Review Article

VGLUTs in Peripheral Neurons and the Spinal Cord: Time for a Review

Pablo R. Brumovsky

Faculty of Biomedical Sciences, Austral University, Avenida Juan D. Perón 1500, 1629AHJ Pilar, Buenos Aires, Argentina

Correspondence should be addressed to Pablo R. Brumovsky; pablo_brumovsky@yahoo.com

Received 2 July 2013; Accepted 25 August 2013

Academic Editors: Y. Ohyagi and Y. Wang

Copyright © 2013 Pablo R. Brumovsky. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vesicular glutamate transporters (VGLUTs) are key molecules for the incorporation of glutamate in synaptic vesicles across the nervous system, and since their discovery in the early 1990s, research on these transporters has been intense and productive. This review will focus on several aspects of VGLUTs research on neurons in the periphery and the spinal cord. Firstly, it will begin with a historical account on the evolution of the morphological analysis of glutamatergic systems and the pivotal role played by the discovery of VGLUTs. Secondly, and in order to provide an appropriate framework, there will be a synthetic description of the neuroanatomy and neurochemistry of peripheral neurons and the spinal cord. This will be followed by a succinct description of the current knowledge on the expression of VGLUTs in peripheral sensory and autonomic neurons and neurons in the spinal cord. Finally, this review will address the modulation of VGLUTs expression after nerve and tissue insult, their physiological relevance in relation to sensation, pain, and neuroprotection, and their potential pharmacological usefulness.

1. How VGLUTs Became the “Gold Standard” for the Identification of Glutamatergic Neurons

Before focusing on the presence and role of vesicular glutamate transporters in neurons in the periphery and the spinal cord, it is important to begin with some historical facts on how it was that glutamatergic neurons were identified in the nervous system. Several decades of research established that glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS) [1] and PNS, including dorsal root ganglion (DRG) and spinal cord neurons [2, 3]. However, the morphological phenotyping of glutamatergic neurons as well as glial cells was not to be a trivial matter.

First in accomplishing a major breakthrough were Storm-Mathisen, Ottersen, and their colleagues who, by means of careful electron microscopy methodologies and meticulous analysis, demonstrated glutamate-like immunoreactivity (Li) in several areas of the mouse, rat, guinea pig, and monkey brain and, importantly, its association to synapses [4–6]. This pioneering work led to the distinction of a “transmitter pool” in glutamatergic terminals, a “metabolic pool” in nonglutamatergic neurons, and a “glial pool” [7–9]. It also prompted the immunohistochemical analysis in sensory neurons, using antibodies against glutamate [10–14]. Subsequent methods to identify glutamatergic neurons were based on the immunohistochemical detection of enzymes like glutaminase, involved in the synthesis of glutamate [15, 16]. This was being reliably done for other neurotransmitters such as catecholamines, serotonin, acetylcholine, and also GABA [17]. More indirect approaches, like the identification of excitatory amino acid transporters (EAATs) located at the cell membrane, both of neurons and astrocytes, and critical for the removal of glutamate released at the synaptic cleft, also emerged [18, 19]. However, since glutamate is a major participant in cell metabolism, even for the synthesis of the inhibitory neurotransmitter GABA [7, 20], and not always the visualization of associated molecules guarantees the glutamatergic nature of neurons, an ideal marker was still sought.

A second breakthrough took place in the mid 1990s, when Ni and collaborators [21] revealed the presence of a brain-specific Na+-dependent inorganic phosphate transporter in the brain of rat pups. Further research showed that this transporter was specific to synaptic vesicles, acted as a
vesicular glutamate transporter (VGLUT), and hence was termed VGLUT$_1$ [22, 23]. Soon afterwards, VGLUT$_2$ [24–30] and VGLUT$_3$ [31–33] were discovered and characterized. Importantly, transfection of GABAergic neurons with DNA encoding VGLUT$_1$ [23] or VGLUT$_2$ [29] conferred the capacity to release both glutamate and GABA, confirming their role in glutamate loading of synaptic vesicles.

Thus, it was the discovery of VGLUTs and the development of selective antibodies and in situ hybridization probes for their detection became the “gold standard” for the characterization of glutamatergic neurons in the brain and brainstem [34–37], the spinal cord [38–43], the peripheral nervous system (PNS) [30, 34, 36, 38, 44–66], and even glia [67–70]. It should, however, be mentioned that neurons coexpressing VGLUT$_1$ [71] or VGLUT$_3$ [3] and the GABAergic marker glutamate decarboxylase have been identified in developing rat hippocampal granule cells (GC), in adult rat hippocampal GCs under intense ionotropic or trophic factor stimulation [71] and in interneurons in the stratum radiatum of the hippocampus [31].

2. Some Neuroanatomical and Neurochemical Details of Peripheral Neurons and the Spinal Cord

2.1. Sensory and Autonomic Ganglia. Sensory impulses, including pain, originating in the surface of the body (e.g., the skin) or deeper structures (e.g., muscles, joints, and viscera) are transmitted to the spinal cord by way of peripheral nerves. These are contributed by thousands of axons produced by sensory neurons (also called primary afferent neurons) contained in the DRGs and cranial ganglia [3]. The great majority of studies analyzing the characteristics of primary afferent neurons focus on “nonvisceral” DRGs, more specifically the 4th and 5th lumbar (L4-5) DRGs, which typically innervate muscles and skin of the leg and foot by way of the sciatic nerve, both in rodents and humans [72].

In contrast, visceral organs are characterized for their innervation by two different “extrinsic” currents: (1) the spinal current, including the pelvic (PN) and the lumbar splanchnic (LSN) nerves [73, 74] and (2) the cranial current, contributed by the vagus nerve [75]. These two currents originate in “visceral” DRG and cranial ganglia neurons, identified by means of retrograde tracing from their peripheral nerve endings in thoracic, abdominal, and pelvic organs. In particular, the PN and the LSN innervating the colorectum or the urinary bladder in rat [73, 76] and mouse [73, 76, 77] carry axons derived from: (1) peripheral projections of thoracolumbar (TL; T8-L1) and lumbosacral (LS; L6-SI) DRG neurons [73, 78]; (2) postganglionic projections of sympathetic neurons contained in the lumbar sympathetic chain (LSC); and (3) sympathetic and parasympathetic neurons present in the “mixed” major pelvic ganglion (MPG) [79–81]. In addition, and unlike other tissues and organs in the body, the gut is also provided with its own “intrinsic” autonomic innervation. This includes sensory and motor autonomic neurons found in the myenteric and submucosal plexuses, from the esophagus to the anus, and collectively referred to as enteric neurons, creating an intrinsic neuronal network [81, 82].

In normal conditions, rodent nonvisceral DRG neurons express a multiplicity of neurotransmitters and receptors, often in different combinations, and are generally considered glutamatergic [83, 84]. Three main subpopulations of DRG neurons have been characterized, including: (1) large and medium-sized neurons expressing NF-200; (2) small and medium-sized neurons expressing the calcitonin gene-related peptide (CGRP) and termed “peptidergic”; and (3) small and medium-sized “nonpeptidergic” neurons expressing components of the receptor for the glia-derived neurotrophic factor and binding of isolecitin B4 (IB4; from the plant Griffonia simplicifolia I) to neuronal glycoproteins and glycolipids [83, 84]. However, the “nonpeptidergic” term should only be applied to subpopulations lacking CGRP, since colocalization between IB4 and CGRP has been shown in rats [85] and mouse [86]. Interestingly, and highlighting the neurochemical complexity of DRG neurons, subpopulations of nonvisceral DRG neurons, lacking both neuropeptides and/or IB4 while expressing the noradrenergic marker tyrosine hydroxylase (TH) [87] or the neuropeptide tyrosine receptor type 2 (Y2R) [88], have also been described.

Several molecules involved in pain sensing (nociception) are expressed by nonvisceral DRG neurons, including the already mentioned CGRP, the transient receptor potential cation channel, subfamily V, member 1 (TRPV1) [89], the P2X purinoceptor 3 (P$_2$X$_3$) [90], or the sodium channel NaV1.8 [91]. Finally, other transmitter candidates in DRG neurons are the nucleotide adenosine-triphosphate (ATP) [92, 93], the “gaseous” transmitter nitric oxide [93, 94], and neurotrophic factors such as the glial- and the brain-derived neurotrophic factors [83].

Visceral DRG neurons, like nonvisceral ones, are classically described as being glutamatergic [14] and normally coexpress a variety of molecules, including neuropeptides [95]. Thus, CGRP is synthesized by rat [76, 96–98] and mouse [76, 77] visceral sensory neurons. TRPV$_1$, P$_2$X$_3$, IB4 [73], and even TH [99] are also expressed by visceral sensory neurons.

Autonomic neurons are morphologically characterized as sympathetic or parasympathetic, based on their expression of noradrenaline (using TH or the norepinephrine transporter type 1 for identification) or acetylcholine (using choline acetyltransferase or the vesicular acetylcholine transporter (VACHT) for identification), respectively. However, it should be noted that some sympathetic neurons have also been shown to coexpress acetylcholine and neuropeptides [80, 100–102]. Finally, different subpopulations of enteric neurons in the myenteric and submucosal plexuses typically express markers such as TH, VACHT, nitric oxide synthase, and several neuropeptides [103].

2.2. Spinal Cord. Peripheral stimuli processed by primary afferent neurons are transferred to the spinal cord by way of their central axons (dorsal roots). In this manner, they penetrate the gray matter, which is divided into 9 laminae, from dorsal to ventral, and an area around the central canal (area X), as originally characterized through analysis of the
morphology and arrangement of Nissl-stained cell bodies in transverse sections of the cat spinal cord [104]. Neurons in each laminae are arranged in a complex but ordered manner, based on morphology, neurochemical composition, and specific sensory modalities [105–107]. Thus, lamina I, the most superficial of all, receives cutaneous A\(\delta\) - and C-fibers [108–111] and muscle and articular afferents [112, 113], as well as visceral afferents [114–116]. Laminae II, subdivided into outer (Iio) with densely packed cells and inner (II) [117], receives predominantly unmyelinated C-fiber afferents [110, 112, 118, 130–132]. In addition, A\(\delta\) -fibers terminate mostly in lamina Iio [121], and some cutaneous mechanoreceptive A\(\beta\)-fibers reach lamina II via lamina III [120, 122–125]. A\(\alpha\)/\(\beta\)-fibers are the main afferent projections to lamina III–VI [110, 112, 123–129]. However, a subpopulation of fine C-fibers also penetrates deeply in the dorsal horn, into lamina III [98, 110, 112, 118, 130–132]. Finally, the area X receives a considerable input of visceral afferents [98, 115, 132–134], although terminals contributed by somatic afferents are also present [129, 135].

3. Expression of VGLUTs in Peripheral Visceral and Nonvisceral Glutamatergic DRG and Cranial Sensory Neurons

3.1. Somatic Expression of VGLUTs. The expression of VGLUT\(_1\) mRNA in large and some medium-sized L4-5 DRG neurons was first shown (although not quantified) in the rat [48, 51]. Subsequent analysis in the mouse [53, 54] revealed presence of VGLUT\(_1\)-IR neurons in 12% to 37% of nonvisceral DRG neurons (Figure 1, Table 1), while its transcript has been detected in ~45% of L4-5 DRG neurons of large and medium size [136]. Immunohistochemical signal for VGLUT\(_1\) is also observed in large and medium-sized visceral DRG neurons projecting to the mouse colorectum (12% [61]) and urinary bladder (32% [62]) (Figure 1, Table 1). Variations between the reported proportions of VGLUT\(_1\)-expressing DRG neurons may depend on: (1) differences in protein and gene regulation between DRG levels (TL versus LS versus L4-5); (2) the use of different VGLUT\(_1\) antibodies/probes, immunohistochemical and in situ hybridization techniques or even mouse strains; and (3) especially when it comes to transcript versus protein mismatches, differential regulatory mechanisms.

In contrast to VGLUT\(_1\), VGLUT\(_2\) has been found in a large proportion of DRG neurons, spanning different cell soma sizes (Figure 1, Table 1), as initially shown in immunohistochemical studies in DRGs targeting the rat ileum [44] or in situ hybridization analysis of lumbar nonvisceral DRGs [51]. In the mouse, from ~65% [54] and up to 90% [137] VGLUT\(_2\)-IR NPs are present in L4-5 DRGs. Even higher percentages of VGLUT\(_2\)-IR NPs have been described in visceral DRG neurons innervating the colorectum [61] or the urinary bladder [62]. Confirming the abundance of VGLUT\(_2\) in DRG neurons, up to 70% [136] or 82% [137] of mouse L4-5 DRG neurons have been shown to express VGLUT\(_2\) mRNA.

Identifying VGLUT\(_3\) in peripheral sensory neurons has been more difficult than for the other VGLUTs, mainly due to the unavailability of antibodies that reliably labelled DRG neurons (in fact, this is still the case today). However, using transgenic mice expressing the enhanced green fluorescent protein (EGFP) under the control of VGLUT\(_3\) regulatory sequences, Seal et al. [66] showed that around 10–11% of nonvisceral lumbar DRG neurons express VGLUT\(_3\) [66]. This has been recently confirmed by in situ hybridization, with detection of VGLUT\(_3\) mRNA in ~17% of nonvisceral DRG NPs [65, 136], and through the identification of ~19% of transgenic adult mouse nonvisceral DRG NPs expressing the reporter gene Tomato, under the control of the VGLUT\(_3\) promoter [65] (Figure 1, Table 1). VGLUT\(_3\) is also present in subpopulations of visceral sensory neurons innervating both the colorectum (~10%, Figure 1, Table 1) or the urinary bladder (~18% [62]). VGLUT\(_3\) appears mostly expressed in small and medium-sized adult DRG NPs [62, 65, 66, 136]. However, a transient versus persistent expression of VGLUT\(_3\) has been proposed, where the transporter is found in large and medium-sized myelinated nonvisceral DRG neurons only during prenatal stages, with the small neuron population remaining VGLUT\(_3\)-expressing during the adult life [65].

In DRGs projecting to visceral organs, an additional peculiarity is observed. Thus, TL and LS DRGs innervating the mouse colorectum [61] or the urinary bladder [62] contain different proportions of neurons expressing VGLUT\(_1\), VGLUT\(_2\), or VGLUT\(_3\) (see Table 2), whilst VGLUT\(_1\) is equally abundant at both DRG levels [62]. Similar variations were also observed for other markers. For instance, the transient receptor potential cation channel, subfamily A, member 1 (TRPA\(_1\)) mRNA is abundant in mouse TL bladder neurons but scarce in LS bladder neurons [138]. On the contrary, TH protein is expressed in threefold (colorectum) and fivefold (urinary bladder) greater proportions in mouse LS DRGs than in TL DRGs [62]. Interestingly, it has been postulated that differences in neurochemical expression between DRG levels could have an impact in the electrophysiological properties of TL and LS visceral afferent neurons [139, 140], as shown in the mouse colorectum, where a higher expression of TRPV\(_1\) in TL than in LS DRGs corresponds with a more robust response to applied capsaicin in colorectal TL nerve terminals [140].

The frequent association of VGLUT\(_1\)-Li to the plasma membrane in nonvisceral [54] and visceral [61, 62] DRG neurons (Figure 1) has raised the question of if somatic glutamatergic release was possible in these neurons [54]. Accumulating evidence suggests that messenger molecules in general are released from the somatic compartment of the neuron [146], including DRG neurons [147–150]. Thus, neuropeptides [147, 148], ATP [149], and even genetically expressed macromolecular tracers in DRG neurons [150] have been shown to undergo somatic release. Interestingly, recent studies in Xenopus oocytes transfected with VGLUT\(_2\) suggest that this transporter can be found in two different states: (1) serving the traditional role of packaging glutamate into synaptic vesicles for \(Ca^{2+}\)-dependent exocytosis, and (2) participating in \(Ca^{2+}\)-independent leakage when present in the plasma membrane [151]. Moreover, this dual role appears to be also true for VGLUT\(_1\) and VGLUT\(_3\) [151]. Whether such states are also a feature in sensory neurons, and VGLUTs
Figure 1: Broad VGLUT expression in mouse visceral and nonvisceral DRG neurons. Bright-field (a)–(c) and immunofluorescence (d)–(l) photomicrographs of DRG sections incubated with VGLUT1, VGLUT2, or VGLUT3 antisense riboprobes ((a), (b), (c), resp.) or VGLUT1 ((d), (g), (j)), VGLUT2 ((e), (h), (i), (k)), or EGFP ((f), (l)) antibodies (EGFP, used as a reporter of VGLUT3 expressing neurons). Colocalizations with CGRP ((d)–(f), (j)–(l)) or IB4 ((g), (h)) are also shown. Colorectum ((j), (l)) or urinary bladder (k) DRG neurons are exposed by presence of the retrograde tracer FB ((j), (k), (l)). (a)–(c) VGLUT transcripts are detected in nonvisceral DRGs, VGLUT1 mostly in large and medium-sized NPs (black double arrowheads in (a)), VGLUT2 in many NPs spanning different cell body sizes (black double arrowheads in (b)), and VGLUT3 in a discrete number of usually small and some medium-sized NPs (black double arrowheads in (c)). Many NPs lacking VGLUTs are also detected (white double arrowheads in (a)–(c)). (d)–(f) The distribution of VGLUT1- (arrowheads in (d)) VGLUT2- (arrowheads and black double arrowheads in (e)), and EGFP-IR (arrowhead in (f)) nonvisceral DRG NPs correlates with the transcript counterparts shown in (a)–(c). While most CGRP-expressing nonvisceral DRG NPs coexpress with VGLUT2 (black double arrowheads in (e)), VGLUT1-(arrowheads in (d), (f)), and CGRP-IR (arrows in (d), (f)) NPs virtually always appear as independent subpopulations. Many VGLUT2-IR DRG NPs lacking CGRP are also detected (arrowheads in (e)). (g), (h) IB4 is virtually always present in VGLUT2-IR nonvisceral DRG NPs (black double arrowheads in (h)), while many other VGLUT1-only NPs are also observed (arrowheads in (h)). In contrast, VGLUT1- (arrowheads in (g)) and IB4-expressing (arrows in (g)) DRG NPs always belong to different subpopulations. (i) VGLUT2-membrane staining is detected in a number of nonvisceral DRG NPs (small arrowheads). ((j)–(l)) VGLUT1- (arrowheads and with double arrowhead in (j)), VGLUT2- (arrowheads and black double arrowheads in (k)), and EGFP-IR (arrowheads and white double arrowheads in (l)) are detected in visceral DRG NPs, with a similar cell soma distribution as observed for nonvisceral DRGs. CGRP-IR visceral DRG NPs are virtually always VGLUT2-IR (black double arrowheads in (k)), while NPs expressing the peptide (arrows in (j), (l)) and VGLUT1 (arrowheads and double arrowheads in (j)) or EGFP-IR NPs (arrowheads and double arrowheads in (l)) belong to different subpopulations. Scale bars: 50 μm ((c) = (a), (b); (h) = (d)–(g); (k) = (j), (l)); 20 μm (i). Data in figures (f) and (l) is previously unpublished, and the tissue has been processed according to the immunohistochemical procedures described in [54, 60–62].
Table 1: Percentage of DRG neurons (visceral or nonvisceral) expressing VGLUTs (protein and mRNA).

| VGLUT     | Species | Percent nonvisceral afferents | Percent visceral afferents (target organs) |
|-----------|---------|-------------------------------|------------------------------------------|
| VGLUT₁ protein | Mouse   | ~37% [53]; ~12% [54] | ~12% (Colorectum [61]); ~32% (U. Bladder [62]) |
|           | Rat     | Detected, not quantified [48] | NE (Colorectum, U. Bladder) |
| VGLUT₁ mRNA | Mouse   | ~40% [136] | NE (Colorectum, U. Bladder) |
|           | Rat     | Detected, not quantified [48] | NE (Colorectum, U. Bladder) |
| VGLUT₂ protein | Mouse   | ~65% [54] | ~97% (Colorectum [61]); ~94% (U. Bladder [62]) |
|           | Rat     | NE | Detected, not quantified (Stomach and Ileum [44]); NE (Colorectum, U. Bladder) |
| VGLUT₂ mRNA | Mouse   | ~70% [136] | NE (Colorectum, U. Bladder) |
|           | Rat     | NE | NE (Colorectum, U. Bladder) |
| VGLUT₃ Protein | Mouse   | ~10% [66]; ~19% [65] | ~10% (Colorectum) |
|           | Rat     | NE | NE (Colorectum, U. Bladder) |
| VGLUT₃ mRNA | Mouse   | ~17% [136]; ~16% [65] | NE (Colorectum, U. Bladder) |
|           | Rat     | NE | NE (Colorectum, U. Bladder) |

NE: not evaluated; *unpublished data; tissue has been processed and NPs quantified according to references [54, 60–62].

Table 2: Percentage of colorectal or urinary bladder DRG neurons expressing VGLUTs protein.

| Target organ | DRG level | VGLUT₁ | VGLUT₂ | VGLUT₃ |
|--------------|-----------|--------|--------|--------|
| Colorectum   | Thoracolumbar | ~15% [61]; ~98% [61] | ~17%* | ~10% [66]; ~19% [65] |
|              | Lumbosacral  | ~8% [61]; ~97% [61] | ~4%* | ~17% [136]; ~16% [65] |
| Urinary bladder | Thoracolumbar  | ~39% [62]; ~94% [62] | ~28% [62] | |
|              | Lumbosacral  | ~26% [62]; ~94% [62] | ~8% [62] | |

*Unpublished data; tissue has been processed and NPs quantified according to references [54, 60–62].

Finally, cranial sensory neurons are richly provided with VGLUTs, and their expression varies between target organs (Table 3).

3.2. Neurochemical Phenotype of VGLUT-Expressing DRG Neurons. As described in Section 2.1, DRG neurons can be divided into peptidergic and nonpeptidergic. VGLUT₁-IR DRG neurons, either nonvisceral [48, 53, 54] or visceral [61, 62] appear to be nonpeptidergic and lacking IB4 (Figure 1, Table 4) or TH (Figure 2), as shown in rat [48] and mouse [53, 54, 61, 62]. Li et al. [46] and Alvarez et al. [50], however, have reported that VGLUT₁ may be found in neuropeptide containing afferents terminating in the laminae I and II of the rat dorsal horn. This suggests that some peptidergic DRG neurons in the rat may synthesize low levels of VGLUT₁, only detected in primary afferent terminals in the spinal cord but not in the larger cell bodies, where the immunohistochemical signal may be “diluted”.

Sharing some similarities with VGLUT₁, VGLUT₃ is expressed in nonvisceral DRG neurons lacking CGRP, only in around 7% of those binding IB4 [66] (Figure 1, Table 4), but in most cases coexpressing with TH (Figure 2), the latter being typically detected in nonpeptidergic, nonvisceral DRG neurons [87]. Accordingly, in visceral DRG neurons targeting either the colorectum (Figure 1) or the urinary bladder [62], VGLUT₃ has only been detected in the nonpeptidergic subpopulation (Table 4).

In contrast to VGLUT₁ or VGLUT₃, a considerable number of VGLUT₂-IR DRG neurons coexpress CGRP or IB₄ in nonvisceral [54] as well as visceral [61, 62] mouse DRGs (Figure 1, Table 4). Conversely, virtually all DRG neurons expressing CGRP or binding IB₄ synthesize VGLUT₂. This is in agreement with the considerable colocalization of VGLUT₂ and IB₄ previously described in primary afferents in the rat dorsal horn [45, 46, 49, 50] and mouse DRG neurons [53] and the previously shown colocalization of glutaminase with CGRP [152] and of glutamate-Li with CGRP or substance P in rat [11, 14, 153]. Accordingly, colorectal—[61] and urinary bladder-projecting [62] DRG neurons often coexpress VGLUT₂ and CGRP (Figure 1, Table 4). Finally, virtually all VGLUT₂-expressing nonvisceral DRG neurons in the mouse express TH (Figure 2), and in rat [154] and mouse [155], colocalization with TRPV₁ has also been reported.

3.3. VGLUTs Colocalization in Cranial and DRG Neurons. It is now clear that at least some neurons in the nervous system express more than only one type of VGLUT. This was not the understanding when VGLUTs were first described. Thus, initial observations in the adult mammalian CNS showed a complementary distribution for VGLUT₁ and VGLUT₂ [26, 28, 30, 156, 157]. Moreover, this complementarity seemed to extend to the synaptic level, where both VGLUTs appeared...
Table 3: Presence of VGLUTs protein in cranial sensory neurons and their projections (upper part, VGLUTs presence in retrogradely traced cranial sensory neurons; lower part, immunohistochemical detection of VGLUTs in nerve terminals of cranial sensory neurons).

| Organ/species | Cranial ganglia | VGLUT₁ | VGLUT₂ | VGLUT₃ |
|---------------|-----------------|--------|--------|--------|
| Rat stomach   | Nodose           | +      | +      | NE     |
| Rat aortic depressor nerve | Nodose | Not detectable | +      | +      |
| Guinea pig trachea [58] | Nodose | +      | +      | NE     |
| Mouse tongue [143] | Geniculate | +      | +      | NE     |
| Rat cornea [45] | Trigeminal | +      | +      | NE     |

| Organ/species | Nerve/terminals | VGLUT₁ | VGLUT₂ | VGLUT₃ |
|---------------|-----------------|--------|--------|--------|
| Rat pleura [56] | Laminar endings | +      | +      | NE     |
| Rat heart [141] | Cardiac vagal afferents | +      | Not detectable | Not detectable |
| Guinea pig trachea [58] | Cough mecanoreceptors | +      | +      | NE     |
| Mouse tongue [143] | Taste Buds | +      | +      | NE     |
| Rat masseter muscle [144] | Mesencephalic projections | +      | NE     | NE     |
| Rat cornea [59] | Trigeminal | +      | +      | NE     |
| Human teeth [63] | Trigeminal | +      | +      | NE     |
| Rat lung [145] | Pulmonary neuroepithelial bodies | NE | +      | NE     |

+: present; NE: not evaluated.

Table 4: Percentage of DRG neurons (visceral or nonvisceral) expressing VGLUTs and CGRP, IB4, or other VGLUTs.

| Colocalization | Species | Percent nonvisceral afferents | Percent visceral afferents (target organ) |
|---------------|---------|-------------------------------|----------------------------------------|
| VGLUT₁ also CGRP | Mouse | Not detectable [53, 54] | Not detectable (Colorectum [61], U. Bladder [62]) |
| VGLUT₁ also CGRP | Rat | Not detectable [48] | NE (Colorectum, U. Bladder) |
| VGLUT₁ also IB4 | Mouse | Not detectable [53, 54] | NE (Colorectum, U. Bladder) |
| VGLUT₁ also IB4 | Rat | NE | NE (Colorectum, U. Bladder) |
| VGLUT₂ also CGRP | Mouse | ~31% [54] | ~81% (Colorectum [61]) |
| VGLUT₂ also CGRP | Rat | NE | ~53% (U. Bladder [62]) |
| VGLUT₂ also IB4 | Mouse | ~42% [54] | NE (Colorectum, U. Bladder) |
| VGLUT₂ also IB4 | Rat | NE | NE (Colorectum, U. Bladder) |
| VGLUT₃ also CGRP | Mouse | Not detectable [66] | Not detectable (Colorectum*, U. Bladder [62]) |
| VGLUT₃ also CGRP | Rat | NE | NE (Colorectum, U. Bladder) |
| VGLUT₃ also IB4 | Mouse | ~7% [66] | NE (Colorectum, U. Bladder) |
| VGLUT₃ also IB4 | Rat | NE | NE (Colorectum, U. Bladder) |
| VGLUT₂ also VGLUT₁ | Mouse | ~14% [54] | Highly likely (Colorectum [61], U. Bladder [62]) |
| VGLUT₂ also VGLUT₁ | Mouse | ~100%* | Highly likely (Colorectum [61], U. Bladder [62]) |
| VGLUT₁ also VGLUT₃ | Mouse | Not detectable* | NE (Colorectum, U. Bladder) |
| VGLUT₂ also VGLUT₃ | Mouse | Not detectable | NE (Colorectum, U. Bladder) |

NE: not evaluated; * unpublished data; tissue has been processed and NPs quantified according to references [54, 60–62].

segregated in physiologically different synapses in the CNS [26, 30, 158, 159]. However, the finding of glutamatergic terminals in the rat hippocampus, containing both VGLUT₁ and VGLUT₂, suggested the possibility of a supplementary distribution [157].

Such a possibility is in fact also a feature in the periphery. Thus, in rat trigeminal ganglia [45] and nonvisceral DRGs [51], coexpression of VGLUT₁ and VGLUT₂ protein or mRNA has been reported in a subpopulation of neurons, respectively. This was confirmed in mouse (Table 4), were a moderate coexpression of VGLUT₁ and VGLUT₂ was shown in some medium-sized and large nonvisceral DRG neurons [54]. Coexpression of VGLUT₃ and VGLUT₂ (but not VGLUT₁) is also detected in nonvisceral DRGs (Figure 2, Table 4). Finally, the overwhelming presence of VGLUT₂ in virtually all colorectal [61] and urinary bladder [62]
Figure 2: Frequent coexpression of VGLUT2 or EGFP (VGLUT3) with TH or VGLUT2 and EGFP in mouse nonvisceral DRG neurons. Immunofluorescence photomicrographs of nonvisceral DRG sections incubated with VGLUT1 ((a), (d)), VGLUT2 ((b), (e)), or EGFP antibodies ((c), (d), (e)). ((a)–(c)) While virtually no VGLUT1-IR (arrowheads in (a)) DRG NPs coexpress with TH (arrows in (a)), most VGLUT2- or EGFP-IR NPs present with TH-Li (black double arrowheads in (b), (c)). Abundant VGLUT2- (arrowheads in (b)), EGFP- (arrowheads in (c)), and some TH-only (arrows in (c)) expressing NPs are also detected. ((d), (e)) Lack of coexpression is observed between VGLUT1 (arrowheads in (d)) and EGFP (arrowheads in (d)). In contrast, EGFP is virtually always coexpressed with VGLUT2 in DRG NPs (double black arrowheads in (e)). Many other VGLUT2-only expressing DRG NPs are also detected (arrowheads in (e)). Scale bars: 30 μm ((c) = (a), (b); (e) = (d)). Data in figures (a)–(e) is previously unpublished, and the tissue has been processed according to the immunohistochemical procedures described in [54, 60–62].

DRG neurons, indirectly implies a considerable degree of colocalization with VGLUT1 or VGLUT3.

How coexpression of two VGLUTs in the same neuron influences its role in neurotransmission is not yet known. It has, however, been suggested that VGLUT expression may be associated with different patterns of neurotransmitter release. Thus, VGLUT1 is normally expressed in CNS neurons with low probability release (climbing fibers in the cerebellum), whereas VGLUT2 would be associated to those with high probability (parallel fibers in the cerebellum) [160]. Whether the type of VGLUT expressed in a single DRG neuron or the coexpression of more than one VGLUT have an impact on release probability remains to be established.

3.4. VGLUTs in the Peripheral Projections of Cranial and DRG Neurons. VGLUTs in peripheral nerves were first identified in rat, mouse [161, 162], and guinea pig [163] esophageal intraganglionic laminar endings (IGLEs), dependent on vagal afferents, and shown to contain VGLUT2. VGLUT1 was also found in esophageal IGLEs in the guinea pig [163] and rat [164] but not the mouse [165]. Subsequent studies revealed presence of VGLUTs in peripheral nerves in many other locations in the upper body (Table 2).

VGLUTs are also present in axonal terminations of abdominopelvic organs in the guinea pig [166] and mouse [61, 62, 167], where VGLUT2 appears to be the main player. Thus, VGLUT2-Li is found in abundant varicosities around VGLUT2-negative mouse colorectal myenteric plexus neurons (Figure 3) [61], in agreement with observations in the guinea pig [166] and mouse rectum [167], and supporting data on guinea pig small intestine showing glutamate-Li with a similar distribution [168]. VGLUT2 is also detected in an overwhelming number of nerve endings terminating in the urinary bladder (Figure 3) [62]. Unlike VGLUT2, VGLUT1 is only found in very few nerve fibers in the mouse colorectum [61], and in a small number of fibers in the urinary bladder, mostly within the muscular layers of this organ (Figure 3) [62]. Discrete VGLUT1 expression has also been reported
in the Pacinian corpuscle and associated neurites in the cat mesentery [55]. The disparate representation of VGLUT1 and VGLUT2 in peripheral nerves terminating in visceral organs is supported by Olsson et al. [166], showing that ~3% of anterogradely traced guinea pig rectal nerve varicosities terminating in the myenteric plexus contain VGLUT1, whereas ~11% exhibit VGLUT2-Li.

In the skin, the immunohistochemical presence of VGLUT1 and VGLUT2 has been studied in mouse [54] and rat [52, 169]. Thus, VGLUT1 is discretely expressed in dermal and epidermal nerves of the glabrous (hairless) skin, in the piloneural complex in hairy skin of mouse (Figure 4) [54], and in rat primary afferent endings in the muscle spindles in the triceps surae muscle [52]. Conversely, VGLUT2 is detected not only in piloneural complexes in hairy skin, but also in numerous nerve endings terminating in the glabrous hindpaw skin (Figure 4), both in deep dermal bundles as well as in close relation to the epidermis, often contacting VGLUT2-IR Merkel cells [54]. The presence of both VGLUT1- and/or VGLUT2-IR fibers in the piloneural complex suggests their origin in glutamatergic DRG neurons producing myelinated D-fibers [170].

Peripheral nerve endings containing VGLUT1 have been more difficult to analyze than those expressing VGLUT1.
Figure 4: Distribution of VGLUT-containing peripheral nerve fibers in the mouse skin. Immunofluorescence photomicrographs of sections of the glabrous ((a), (c)) and hairy skin ((b), (d)) incubated with VGLUT1 ((a), (b)) or VGLUT2 ((c), (d)) antibodies. ((a), (b)) VGLUT1-IR nerve fibers are discretely observed in the glabrous (double arrowheads in (a), showing nerve fibers in close proximity to the epidermis) and the hairy skin (black double arrowheads in (b), showing the follicular neural network; white double arrowheads showing fibers lying in the basal membrane of the epidermis). ((c), (d)) Abundant VGLUT2-IR nerve fibers are detected in the glabrous (arrowheads in (c), showing nerve endings penetrating the epidermis) and the hairy skin (black double arrowheads in (d), showing the follicular neural network; white double arrowheads, showing nerve endings in the dermis and epidermis). Scale bars: 50 μm ((c) = (a); (b); (d)). Figures (b) and (d) are reproduced in part, and with permission, from [54].

VGLUT1-containing varicosities have also been reported in the esophageal myenteric plexus of rat [161]. Since a small subpopulation of VGLUT2-IR mouse colorectal DRG neurons is nonpeptidergic (~18%), it could be postulated that they selectively innervated the myenteric plexus. Alternatively, these nonpeptidergic VGLUT2-IR nerve fibers in the myenteric plexus could derive from neurons in the LSC or the MPG, two major contributors of nerve fibers in the colorectum [79] and the urinary bladder [172]. However, only rarely VGLUT2-IR neurons are observed in normal conditions in these ganglia [61, 62].

Finally, coexpression of VGLUTs in peripheral nerve endings has been shown for VGLUT1 and VGLUT2 in rat [164] and mouse [165] (but not in guinea pig [163]) GLEs [173]. Also, Merkel cells in the rat sinus hair follicle express VGLUT2 and often show colocalization with VGLUT1 [169].

4. Expression of VGLUTs in the Spinal Cord

Thinly myelinated or unmyelinated low threshold Aδ- and C-fibers transmitting nociceptive information and terminating predominantly in the superficial layers (laminae I and II) of the spinal dorsal horn release glutamate [174, 175]. Local spinal cord neurons are also capable of synthesizing and utilizing glutamate as their major excitatory neurotransmitter [3, 176, 177]. However, dissecting the patterns of expression...
and morphology of glutamatergic primary afferent terminals and spinal cord neurons from a “VGLUT perspective” has been challenging, mainly due to the failure of virtually all available VGLUT antibodies to produce immunohistochemical signal in the cell bodies of spinal cord neurons and the complex contribution of nerve terminals in the area (primary afferent versus local neurons, dendritic and axonal projections versus descending fibers). Nevertheless, the combined knowledge derived from immunohistochemical [30, 40, 46, 48–50, 54, 64, 66, 178–186] and in situ hybridization [43, 48, 51, 136, 187] studies allow today for a rather complete depiction of the VGLUT scenario in the spinal cord.

Thus, VGLUT$_1$- and VGLUT$_2$-Lis are easily detected in the neuropil of the gray matter in the spinal cord, although both transporters appear distributed differently between laminae (Figure 5). In rat [30, 40, 46, 48, 50] and mouse [54], VGLUT$_1$ -Li is strong in laminae III–IV, medial laminae V/VI, dorsal lamina VII, and around lamina IX motoneurons. In contrast, VGLUT$_1$ -Li is weak in laminae I, IIo, the lateral part of lamina V, the lateral spinal nucleus, and lamina VIII. Regarding VGLUT$_2$, studies in rat [30, 46, 48, 50] and mouse [54] exposed its abundant presence in laminae I and IIo, areas known to receive nociceptive fibers. Deeper in laminae IV–V, VGLUT$_2$ -Li appears moderate but progressively increases towards the ventral horns. As for VGLUT$_3$, either through detection of weak VGLUT$_3$ and stronger EGFP immunohistochemical signals in transgenic mice, presence of the transporter has been shown in the neuropil of laminae I–II neuropil (Figure 5) [66]. The question is, how are these different immunohistochemical patterns generated?

DRG neurons are undoubted contributors of VGLUT$_1$-containing nerve fibers in the spinal cord. Varoqui et al. [30]
were the first in suggesting this and later confirmed by studies showing that transganglionically labelled primary afferent terminals in the dorsal horn of the spinal cord of rat expressed VGLUT$_1$- or VGLUT$_2$-Li [49]. Further support came from studies using dorsal rhizotomy, a procedure that completely blocks the central axonal transport of molecules produced by DRG neurons. Thus, dorsal rhizotomy dramatically, but not completely, reduces VGLUT$_2$-Li in the ventral horn (and to a lesser extent also in the dorsal horn), both in rat [46, 48, 50] and mouse [54].

However, the persistence of at least some VGLUT$_1$-Li after dorsal rhizotomy suggests additional sources, including: (1) primary afferents expressing this transporter and entering the spinal cord at levels higher and lower to the lesion and travelling certain distances before contacting their second order neurons; (2) local dorsal horn neurons; (3) brainstem-[48, 178] and cortical-derived [26, 178, 179] nerve terminals. Supporting the local origin, oligo- and riboprobe, radioactive or nonradioactive in situ hybridization studies by Kullander et al. [187] in neonatal mice, and Oliveira et al. [48] and Llewellyn-Smith et al. [40] in adult rats, revealed a few large VGLUT$_1$ mRNA-positive neurons in the dorsomedial part of the intermediate zone of the dorsal horn of the thoracic spinal cord, resembling dorsal nucleus of Clarke neurons. Studies in adult rats also suggested presence of VGLUT$_1$ mRNA-positive neurons in the lamina I of the dorsal horn [51], as well as in motoneurons (Figure 5) [43, 51]. More recently, in a study in adult mouse, we confirmed the expression of VGLUT$_1$ mRNA in a small group of neurons also resembling the dorsal nucleus of Clarke, and in occasional deep dorsal horn neurons at thoracolumbar levels [136]. Other spinal neurons, including motoneurons or superficial dorsal horn neurons, lacked VGLUT$_1$ [136]. The presence of VGLUT$_1$ in the dorsal nucleus of Clarke, known to be the origin of the spinocerebellar pathways [188], is supported by the detection of abundant VGLUT$_1$-Li in nerve fibers terminating in the anterior and posterior zones of the cerebellum [180], normally receiving spinocerebellar mossy fibers [181].

With one exception in the rat showing an ipsilateral decrease [46], dorsal rhizotomy appears unable to alter the immunoreactivity of VGLUT$_2$ in the dorsal horn of both rat [48, 50] and mouse [54]. This suggested that most if not all VGLUT$_2$-Li was dependent on local or supraspinal neurons. In fact, supraspinal sources of VGLUT$_2$ in the spinal cord have been recently demonstrated, as shown by their immunohistochemical presence in rubrospinal, vestibulospinal and reticulospinal tracts in rat [178]. However, a great proportion of VGLUT$_1$-Li in the spinal cord is likely dependent on numerous spinal cord neurons, as shown by their expression of VGLUT$_2$ transcript in the ventral and lateral aspects of the intermediate zone, in discrete parts of the ventral horns, and in the dorsal horn in rats [40, 48] and mice [136, 187] (Figure 5).

VGLUT$_2$ mRNA-positive neurons in the spinal cord likely belong to both the interneuron [48, 49] and projection neuron subpopulations [40, 48, 51, 136]. On one hand, interneurons in the rat spinal cord of rat expressing somatostatin, neurotensin, substance P, and/or enkephalin coexpress VGLUT$_2$ [49]. More recently, functionally identified excitatory interneurons in the rat have been shown to express VGLUT$_1$-Li [177, 182, 183]. On the other hand, the presence of VGLUT$_2$-Li in the large lemniscal and spinothalamic terminals to the ventral posterior thalamic nuclei in the rat [184] confirms that at least a number of neurons expressing VGLUT$_2$ mRNA in the rat and mouse dorsal horn are projection neurons. Moreover, and as pointed out above, coexpression of both VGLUT$_1$- and VGLUT$_2$-Lis in mossy fibers in the cerebellum [180] indicates that Clarke’s nucleus projection neurons also express VGLUT$_2$. Finally, with the exception of one study in rat, suggesting that both VGLUT$_1$ and VGLUT$_2$ are expressed in motoneurons [43], other studies in rat [40, 48] and mouse [54, 136, 187] report that motoneurons, as well as neurons in area X, lack VGLUT$_2$, at least at the lumbar enlargement. However, motoneurons express other glutamatergic markers such as glutamate itself [185, 189] and/or EAAT-3 [185] and thus may utilize a yet undescribed VGLUT.

Is then the contribution of primary afferents to the VGLUT$_2$-Li in the dorsal horn of the spinal cord completely ruled out? The answer is no since VGLUT$_2$ has indeed been identified in transganglionically labelled primary afferents in the dorsal horn [49], and it modestly accumulates after dorsal root ligation (DRG side of the ligation) [54]. It is thus possible that low quantities of VGLUT$_2$ were transported by the central projections of DRG neurons and that the intense local- and supraspinal-dependent VGLUT$_2$-Li in the spinal cord neuropil acted as a masking factor, potentially explaining lack of changes after dorsal rhizotomy [46]. Interestingly, the neuropeptide tyrosine receptor type 1 (Y$_1$R), normally expressed by small primary afferent neurons, undergoes axonal transport and can be immunohistochemically detected in the dorsal horn, but its signal remains unaffected by dorsal rhizotomy [190]. In this case, and as discussed for VGLUT$_2$, the abundant expression of the Y$_1$R in local dorsal horn neurons appears to mask the expected decrease of the receptor after dorsal rhizotomy [190].

As for VGLUT$_3$, its modest immunohistochemical detection in the superficial dorsal horn has been shown to depend on DRG and to a lesser extent also supraspinal and spinal cord neurons. Thus, (1) dorsal rhizotomy in transgenic mice results in an almost complete disappearance of VGLUT$_3$-regulated EGFP-Li, normally observed in the superficial laminae of the dorsal horn, certifying its peripheral origin [66]; (2) Oliveira et al. [48], reported presence of a VGLUT$_3$-IR neuropil in the sympathetic intermediolateral column (often coexpressing serotonin), supporting their origin in the dorsal and median raphe nucleus, where such localization has already been demonstrated [32, 33]; and (3) VGLUT$_3$ protein [51, 136] and transcript [32, 51, 65, 136] have been demonstrated in the spinal cord of rat [32, 51] and mouse [65, 136], by means of RT-PCR [32] and western blot [51] in spinal cord extracts and by in situ hybridization in tissue sections [51, 65, 136]. More specifically, VGLUT$_3$-expressing neurons have been detected in neurons in the deep dorsal horn and some in the ventral horn of adult rats [51], in the superficial and deep dorsal horn of neonatal mice [65], and in the deep dorsal horn of adult mice [136] (Figure 5). Interestingly,
the VGLUT$_2$-expressing subpopulation of neurons in the superficial layers of the dorsal horn described by Lou et al. in the neonatal mouse [65] is not detected in the adult mouse [136], suggesting developmental regulation of the transporter.

The complex peptidergic versus nonpeptidergic representation of VGLUTs in DRG neurons is also observed in their spinal axonal terminations. The general consensus is that VGLUT$_2$ is often associated with peptidergic nerve terminals [46], whereas VGLUT$_1$ is hardly so [48]. Thus, Li et al. [46] reported that SP-Li is present in ~50% of the VGLUT$_1$-IR primary afferent boutons in laminae II [46]. In support, functional CGRP and AMPA receptors colocalize in single dorsal horn neurons, suggesting that these neurons may receive contacts from primary afferent terminals expressing peptides, glutamate, or both [191]. More importantly, AMPA receptor GluR$_2$-IR puncta can be seen in contact with over 90% of CGRP-IR primary afferent synaptic boutons [192]. However, Todd et al. [49] reported that peptidergic primary afferents in the rat, as well as nonpeptidergic C-fibers, exhibit low levels of VGLUT$_2$-Li or even lack either VGLUT$_1$ or VGLUT$_2$.

Finally, and as observed in mouse DRG neuronal bodies [54], VGLUT$_1$ and VGLUT$_2$ colocalization is also detected in a proportion of primary afferent varicosities in laminae III-IV and IX in the rat spinal cord [49, 50, 179], as well as in the nucleus of the solitary tract [186]. The appearance of these varicosities is described as being “…relatively large… and contained immunoreactivity that was intense for VGLUT$_1$, but weak for VGLUT$_2$” [50].

5. Expression of VGLUTs in Autonomic Ganglia

5.1. Sympathetic and Parasympathetic Ganglia. In normal conditions, LSC neurons do not express VGLUTs [60–62], whereas only occasional VGLUT$_2$-IR neurons are detected in naïve mouse MPG [61, 62]. However, VGLUT$_2$-IR fibers are found in the mouse LSC and the MPG, in the latter forming perineuronal baskets (Figure 3) [60–62], often but not exclusively, around TH-IR MPG neurons [60].

The VGLUT$_2$-IR baskets observed in MPGs appear greatly dependent on extrinsic sources, as demonstrated by their dramatic immunohistochemical disappearance after axotomy of the pelvic nerve [60]. A sympathetic or parasympathetic preganglionic origin [80] for these VGLUT$_2$-IR baskets has been ruled out due to their lack of coexpression with TH or VACHt, respectively. Alternatively, they could derive from primary afferent fibers in their way to pelvic organs and also running through the MPG [80, 193, 194]. In support, Aioun and Rampin [195] have shown the ultrastructural coexistence of glutamate and large dense core vesicles; the latter typically loaded with peptides, in axons and terminals in the rat MPG. In the mouse, however, VGLUT$_2$-IR MPG baskets lack CGRP [60]. Nevertheless, as described above, many nonpeptidergic mouse visceral DRG neurons express VGLUT$_2$ [61, 62]. Whether VGLUT$_2$-IR nonpeptidergic DRG neurons are both the origin of the MPG baskets, as well as of the neuropil surrounding myenteric plexus neurons in the mouse colorectum (see Section 3.4), and participate in sensory-motor coupling remains to be demonstrated. Finally, one additional source could be viscerofugal neurons projecting towards the MPG, found in rat [196], guinea pig [197], and mouse [198]. Interestingly, we recently showed a small subpopulation of myenteric neurons expressing VGLUT$_2$ mRNA in the mouse colorectum [61] (see below).

5.2. Enteric Neurons. Most studies analyzing the expression of glutamate and glutamatergic markers in enteric neurons have focused on proximal rather than distal parts of the gut. Thus, enteric neurons containing immunohistochemically detectable glutamate have been described in the myenteric and submucosal plexuses of rat [168] and guinea pig ileum [168, 199], as well as in myenteric ganglia of the rat stomach [200]. More recently, a study in humans suggested that glutamate was present in large intestine submucosal and myenteric plexuses as well as in nerve fibers innervating the circular muscle layer [201], supporting earlier studies showing basal as well as stimulated (electrical and chemical) release of glutamate presumably from longitudinal muscle myenteric plexus neurons in the guinea pig ileum [202, 203].

As expected, VGLUTs are detected in enteric neurons in the gut. Thus, VGLUT$_1$ was found in cholinergic and nitrergic neurons in rat [161, 164] and mouse [165] esophageal myenteric plexus. VGLUT$_2$ was reported in neurons in the guinea pig, rat, mouse ileum [44, 204] and in rat [164] and mouse [162, 164] esophagus. Even in humans, all three VGLUTs appear to be present in the small intestine myenteric plexus neurons, interganglionic varicose fibers, and perisomatic puncta [205]. In the distal gut, lack of signal of VGLUT$_1$ and VGLUT$_2$ in enteric neurons of guinea pig rectum first suggested absence of glutamatergic enteric neurons, at least in this species [166]. In mouse, however, both protein and transcript of VGLUT$_2$ are found in a small number of colorectal myenteric plexus neurons, scattered throughout the plexus in contrast to VGLUT$_1$ [61] or VGLUT$_3$ (Figure 3), which appear to be absent. What the phenotype of VGLUT$_2$-expressing mouse myenteric plexus neurons is, remains to be established. However, glutamate and substance P or choline acetyltransferase colocalization was reported in small intestine enteric neurons of the guinea pig and rat [168].

6. Effects of Peripheral Nerve Injury or Tissue Inflammation on the Expression of VGLUTs

6.1. Sensory Ganglia and the Spinal Cord. Peripheral nerve injury [84, 207–209] as well as peripheral tissue inflammation [210–212] induces downregulation and upregulation of numerous molecules involved in a variety of functions that include survival, regeneration, and pain transmission in DRG and sympathetic ganglia neurons, as well as motoneurons in the spinal cord [84]. In line with such changes, Al-Ghoul et al. [213] reported an increase in the immunohistochemical levels of glutamate in the superficial layers of the dorsal horn after chronic loose ligation of the sciatic nerve, in parallel with the expected decrease of substance P and CGRP. Such
increase could be related to alterations in VGLUTs synthesis and axonal transport.

In fact, peripheral nerve lesions alter the expression of VGLUTs in primary afferent neurons (Table 5). Thus, Hughes et al. [214] were the first in demonstrating that axotomy of the sciatic nerve in rats induces depletion of VGLUT1 protein in myelinated low threshold cutaneous and muscle mechanoreceptors terminating in the dorsal and ventral horns. It is now known that the depletion of VGLUT1 in the spinal cord is mainly due to its reduced expression in DRG neurons, as shown in mouse [54]. Axotomy of the sciatic nerve in the mouse also reduces the numbers of VGLUT2-IR DRG NPs [54], although it is not known if axotomy also alters its protein expression. It is possible that differences in the techniques (in situ hybridization versus immunohistochemistry) and mouse strains (BalbC versus NMRI mice) between studies explained the discrepancy. However, it is also possible that differences between transcript and protein regulations in DRG neurons after peripheral nerve injury had biological meaning (see Section 7).

Finally, in the only published account so far, inflammation of the hindpaw (using a unilateral intradermal injection of Complete Freund’s Adjuvant) failed to induce changes in the expression of VGLUT1, VGLUT2, or VGLUT3 transcripts, both in DRG or spinal cord neurons [136]. Perhaps in these conditions, changes in expression and physiology of VGLUTs are more relevant in the axon and synaptic zones, where glutamate concentration and production is 2 to 3 times higher than in the cell body [19, 216, 217]. However, whether the inflammation of the hindpaw (or visceral organs) results in changes in VGLUT proteins in DRG neurons and their projections remains to be established.

6.2. Sympathetic Ganglia. Sympathetic neurons are profoundly affected by peripheral nerve injury [84, 101, 102, 209]. Thus, postganglionic axotomy of sympathetic nerves in cat [218] or rodent superior cervical ganglion (SCG) [101, 102, 206] induces downregulation of neuropeptides such as CGRP [218] and NPY, as well as the noradrenergic marker TH [101, 102, 219, 220], and upregulation of galanin [101, 102, 218], VIP, SP [101, 102, 221], and the NPY Y2-receptor [101, 102,
VGLUT2 is upregulated in LSC neurons and occasionally coexpresses with TH. Immunofluorescence photomicrographs of sections of the LSC of mouse after pelvic nerve axotomy, incubated with VGLUT2 ((a), (b)) and ATF-3 (a) or TH (b) antibodies. ATF-3 is used as a marker of injured neurons. (a) Pelvic nerve axotomy results in de novo expression of ATF-3 in an abundant number of LSC NPs (arrows). Pelvic nerve axotomy also results in de novo upregulation of VGLUT2, always coincidental with the upregulation of ATF-3 (double arrowheads). (b) Most VGLUT2-IR LSC NPs observed after lesion lack TH (arrowheads), although occasional VGLUT2/TH-IR NPs are detected (double arrowhead). Abundant TH-IR NPs are present in the LSC (arrows). Scale bars: 10 μm.

206. Also in pigs, the axotomy of colonic nerves containing sympathetic fibers projecting from the LSC, results in the upregulation of galanin and somatostatin, paralleled by the downregulation of TH [222].

Only until recently, glutamate was not thought to be present in autonomic neurons [81]. In fact, apart from a few VGLUT2-IR nerve fibers present in LSCs (more abundant in the stellate ganglion; unpublished results), VGLUTs are not normally expressed by neurons in these ganglia [60–62]. However, axotomy of either the pelvic (visceral) or the sciatic (nonvisceral) nerves results in the upregulation of VGLUT2 in a number of mouse LSC neurons (Table 5, Figure 6) [60].

The lesion-induced VGLUT2 plasticity appears to be selective in that parallel VGLUT1 protein and transcript or VGLUT3 mRNA upregulations are not observed [136]. The majority of VGLUT2-IR LSC neurons detected after injury lack TH, suggesting a parallel downregulation of the noradrenergic marker (see above). However, some LSC neurons upregulating VGLUT2 were shown to coexpress with TH, suggesting the possibility of glutamate and noradrenaline corelease [60] (Figure 6). Coexpression of VGLUT2 [223–228] or glutamate [223] with TH (used as a marker for dopaminergic neurons) has been previously shown in rat [223, 225–228] brainstem and hypothalamus [228]. Alternatively, VGLUT2 could be upregulated in LSC cholinergic (nonnoradrenergic) neurons [229], although this remains to be demonstrated.

The upregulation of VGLUT2 in LSC neurons could represent de novo synthesis of transporter protein and transcript, or an increase from low, undetectable levels. The absence of VGLUT1 or other VGLUTs transcript, using the sensitive riboprobe in situ hybridization techniques suggests the former hypothesis [60]. Considering the importance of VGLUTs for the uploading of glutamate into synaptic vesicles, it could be speculated that some LSC neurons, upon injury, acquire a glutamatergic phenotype, may release glutamate, and could potentially contribute to increased fast synaptic transmission and nociceptive mechanisms [60].

7. VGLUTs Modulation after Peripheral Nerve Injury—Implications to Glutamatergic Neurotransmission

While it is still not known exactly how many VGLUT copies are in each synaptic vesicle [35], it seems intuitive that changes in their expression after tissue insult should have profound consequences in glutamate loading. In fact, several studies where the expression of VGLUTs in synaptic vesicles is genetically manipulated suggest that the type and/or number of VGLUTs matter [19, 35]. For instance, the number of VGLUT copies in a given synaptic vesicle/neuron influences the amount and rate of vesicle loading, the size of glutamatergic quanta, and even the reserve pool of synaptic vesicles [158, 230–232].

In line with the above, the downregulation of VGLUT1 [214] and VGLUT2 proteins [54] observed in DRG neurons after sciatic nerve axotomy, while maintaining unaltered mRNA levels [136], may imply that these neurons sustain transcriptional levels of VGLUT1 and VGLUT2, in order to counteract the downregulation at the cell body level the latter resulting from increased axonal transport, protein use, and depletion at peripheral and central terminals [54]. Interestingly, axotomy of the sciatic nerve in rats results in a reduction in the number of synaptic vesicles in the central terminals of axotomized primary afferents [233], including peptidergic ones [234], suggesting increased fusion of clear synaptic vesicles (likely expressing VGLUTs) to the plasma membrane and glutamatergic release.
However, it should be noted that glutamatergic neurotransmission, from a synaptic vesicle point of view, is influenced by a variety of additional factors, comprising: (1) several steps to produce mature synaptic vesicles, mostly at the axons, although some may already happen in the soma [235]; (2) an active and tight regulation of presynaptic vesicle and transmitter recycling at the level of the synaptic cleft, to counteract depletion in situations of high activity [19, 216, 236]; (3) the extravesicular/cytoplasmic glutamate concentration (regulated by the enzyme glutaminase) 2 to 3 times higher in the terminals than in the cell body [217] and crucial in defining intravesicular glutamate content [19, 216]; (4) chloride conductance, along with the synaptic membrane potential, as also determining the glutamatergic content of synaptic vesicles and involving the participation of VGLUTs [237]; and (5) vesicular size, as it has been shown that there are different naturally occurring sizes that influence the quanta for different neurotransmitters, including glutamate [238]. How all these factors are challenged by peripheral nerve or tissue injury is not yet known. However, it has been shown that glutaminase is upregulated in rat DRG neurons during hindpaw inflammation and that its blockade results in reduced pain-like behaviour [239].

Altogether, nerve injury and/or inflammation and the accompanying pain, may result from changes in the expression of synaptic vesicles, associated proteins (including VGLUTs) and neuronal glutamatergic machinery in general, contributing to a fine “tuning” of pain mechanisms both at the synaptic as well as the cell body levels (see below).

8. VGLUTs, Proprioception, Pain, Survival, and Neuroprotection

8.1. Proprioception. Different studies in the peripheral and nervous systems suggest that proprioception is served by glutamatergic neurons expressing VGLUTs. This hypothesis is based on many of the observations in rodents presented above: (1) VGLUT1 is expressed by a large number of large and medium-sized DRG neurons [48, 51, 54] likely producing myelinated peripheral projections terminating in muscle and joint proprioceptors; (2) VGLUT1-IR DRG neurons project fibers that have been morphologically characterized as proprioceptive [50, 214] towards the ventral horn and establish primary afferent-motoneuron contacts [40, 48–51, 54, 187, 214]; (3) many VGLUT1-IR (likely proprioceptive) fibers also terminate in the deep dorsal horn, in the area occupied by Clarke’s nucleus [48, 50, 54, 136, 187]; (4) Clarke’s nucleus, composed by the second-order neurons giving rise to the spinocerebellar proprioceptive pathway [188] expresses VGLUT1 [40, 48, 136, 187], and likely also VGLUT2 [136, 180]; (5) VGLUT1-Li (and also VGLUT2) is detected in mossy fibers terminating in the anterior and posterior zones of the cerebellum [180], known to receive input from the spinocerebellar pathway described above [181]. In addition, and suggesting a role in the cortical control of motoneurons, pyramidal cells in the neocortex express VGLUT1 mRNA [26], and numerous rat corticospinal tract nerve fibers terminating in the ventral horns exhibit VGLUT1-Li [178, 179].

8.2. Nonvisceral Pain. The use of transgenic mice has exposed a central role for VGLUT2 in the glutamatergic mechanisms associated to nonvisceral pain. Thus, heterozygote VGLUT2 knock-out (KO) mice (homozygote mice experience perinatal death) exhibit impaired mechanical and cold allodynia after spared sciatic nerve injury, despite maintaining normal acute pain responses and increases in pain-like behaviour after inflammation of the hindpaw [240, 241]. Such behavioural patterns after partial VGLUT2-KO originally suggested the involvement of the thalamus, whose neurons are richly provided with VGLUT2 and presented with altered electrophysiological function in the transgenic mice [241]. However, mechanisms involving VGLUT2 and pain appear to be relevant also at the DRG level. Thus, the selective deletion of VGLUT2 in a subpopulation of TH- and TRPV1-expressing neurons in mouse DRGs resulted in increased itch and decreased thermal pain sensitivity [155]. Interestingly, peripheral nerve injury results in VGLUT2-Li increases in small mouse DRG neurons [54] (see Section 6.1), and it is possible that these were TRPV1-expressing (see Section 3.2). Thus, a hypothesis could be that activation of TRPV1 in neurons upregulating VGLUT2 during peripheral neuropathy may contribute to heightened peripheral and/or central release of glutamate, in the latter, resulting in the activation of nociceptive second-order projection neurons present in laminae I-II [242].

Selective deletion of VGLUT2 in another subpopulation of DRG neurons expressing the sodium channel subtype Nav1.8 resulted in altered pain responses, including attenuated responses to intense mechanical stimuli [243]. Interestingly, most of these effects seem to be associated with reductions in glutamate release in the superficial layers of the dorsal horn, as shown by the reduced c-fos activation of local dorsal horn neurons upon noxious heat stimulation [155] or intraplantar injection of capsaicin [244]. Moreover, a reduction in spontaneous excitatory postsynaptic currents was observed in lamina II dorsal horn neurons in the VGLUT2-KO-Nav1.8 mice [244].

Of the other known VGLUTs, VGLUT1, appears mostly associated with proprioception (see above) and the transmission of tactile stimuli, as it has been proposed that many VGLUT1-expressing primary afferent terminals in the superficial and deep dorsal horn correspond to low-threshold cutaneous mechanoreceptors, including those associated with the piloneural complex, in particular for nerve fibers terminating in lamina III of the superficial dorsal horn [49, 50, 214]. Deletion of VGLUT1 in mice has no effect on nonvisceral pain behaviour [240].

On the contrary, VGLUT3 is currently the center of debate. On one hand, deletion of VGLUT3 in mice results in an increased threshold to intense noxious mechanical stimuli and reduced mechanical hypersensitivity to normally innocuous stimuli after tissue inflammation or nerve injury [66]. On the other hand, mice with deleted VGLUT3 through knockout of the runt domain transcription factor Runxl, essential for the developmental control of unmyelinated sensory neurons (nociceptors, pruriceptors, and thermoceptors) [245] and also VGLUT3 in sensory neurons [65], did not show
major changes in acute and chronic mechanical pain, with the exception of a modest increase in mechanical threshold after hindpaw carrageenan injection [65]. However, Seal et al. [66] utilized mice with global VGLUT3 knockout (these mice also having deafness and rare nonconvulsive seizures), and thus, the behavioural effects observed in their study could also be influenced by deletion of the transporter in the spinal cord or other parts of the brain. With some limitations as well, the study by Lou et al. [65] analyzed neurons lacking VGLUT3 but also Runx1, the latter influencing the expression of additional molecules in sensory neurons. Therefore, more research is needed to better understand the role of VGLUT3 in acute and chronic nonvisceral pain.

Finally, the role of VGLUTs in nonvisceral nociception may also extend into the peripheral projections of DRG neurons. This is suggested by the increased glutamate (but not aspartate) levels in the hindpaw extracellular space, upon A- and/or C-fiber stimulation of the sciatic nerve, as well as the local injection of kainate or capsaicin [246]. Such a release of glutamate results in depolarizing effects on primary afferent C-fibers and the induction of pain-related behaviour of exogenously applied glutamate [246–249], likely acting on presynaptic glutamate (auto) receptors of various types [250–254]. The type of VGLUT involved in these mechanisms has not been defined. However, it is possible that VGLUT2 was a main player, as suggested by its abundance in peripheral nerve endings in the skin [54].

8.3. Visceral Pain. The involvement of VGLUTs in visceral pain remains to be elucidated. The only study on the role of VGLUT2 in visceral pain published so far found no differences between VGLUT2-KO and littermate mice [240]. This is curious, especially when considering that the abundant numbers of VGLUT2-expressing colorectal [61] and urinary bladder [62] neurons imply the likely colocalization of the transporter with several molecules associated with nociception, such as TRPV1 [89], P2X3 [90], or the sodium channel NaV1.8 [91], only to cite a few. Thus, TRPV1 is abundantly expressed in rat and mouse colorectal DRG neurons [76,255] and has been associated to mechanisms of chronic visceral pain [256], and coexpression of VGLUT2 with TRPV1 has been previously reported in nerve fibers terminating in the mouse rectum [167]. In addition, P2X3, implicated in nociception [257], particularly in visceral organs [258,259], is also expressed by a proportion of colorectal DRG neurons [77], and a role for Na(V)1.8 in visceral pain and hyperalgesia has also been reported [260]. Therefore, it would be expected that deletion of VGLUT2 in so many neurons clearly prepared for nociception resulted in altered pain mechanisms. More research will be necessary to establish the extent to which VGLUT2 participates in the physiopathology of visceral disorders associated with discomfort and pain.

Finally, preliminary experiments suggest that VGLUT1 may not be involved in visceral hypersensitivity since its deletion does not alter the response to noxious mechanical distension of the colorectum, as compared to control mice (unpublished results). Accordingly, only a small percentage of VGLUT3-expressing DRG neurons innervating the urinary bladder [62] or the colorectum (Figure 1) have been identified. However, an association between changes in the expression of VGLUT3 in DRG neurons and visceral hyperalgesia in rats with Trichinella Spiralis infection has been proposed [64].

8.4. VGLUT-Expressing Sympathetic Neurons: Implications to Pain. The upregulation of VGLUT2 in sympathetic neurons in the LSC (see Section 6.2) positions them as the new “kid on the block”, acting as one additional contributor to peripherally released glutamate [60], along with primary afferents [48,51,53,54,61,62,66,154], and participating in processes of sympathetic-sensory neuron coupling [261,262], also through glutamatergic neurotransmission.

In such scenario, glutamate released from primary afferent nerve terminals could act onto various types of glutamatergic receptors present in sympathetic postganglionic nerves [263–266], promoting an augmented release of noradrenaline and perhaps also glutamate. In turn, such “sympathetically” released glutamate could act on existing glutamatergic receptors in both visceral [267–270] and nonvisceral [175,253,271–275] primary afferent neurons, perpetuating a state of excitation in conditions such as inflammation [266] or nerve injury. More research will be necessary to: (1) assess the role of nerve injury-induced upregulation of VGLUT2 in LSC neurons; (2) explore if its expression is also affected by other types of visceral organs pathological conditions (e.g., ulcerative colitis or interstitial cystitis); and (3) what is the consequence of deleting VGLUT2 on autonomically driven nociceptive mechanisms.

8.5. VGLUTs, Survival, and Neuroprotection. The increased expression of VGLUT2 in LSC neurons appears tightly related to the occurrence of axonal damage, as shown by the concomitant upregulation of the activating transcription factor 3 (ATF-3) [60] (Figure 6), a classical marker of damaged peripheral axons [276]. Anotomy of the rat or mouse superior cervical ganglion postganglionic axons also results in de novo ATF-3 expression [277], although it is not known if VGLUT2 is upregulated in these neurons. Interestingly, ATF-3 [278], as well as the classical nerve growth factor (NGF), are central to mechanisms of nerve regeneration, and neuronal survival [80,209]. Whether the upregulated VGLUT2 (and potentially also glutamate) had a role in the survival and regeneration of LSC neurons remains to be established. However, several studies support such concept. Thus, VGLUT2-Li is present in neurons migrating from the olfactory placode towards the forebrain in the developing rat brain, gradually decreasing toward adulthood [279]. Moreover, an association between the expression of VGLUT2 protein in mesencephalic dopaminergic (DA) neurons and their formation of synaptic junctions in the nucleus accumbens was demonstrated in rat [280]. Furthermore, conditional knockout of VGLUT2 results in reduced growth and survival of mesencephalic DA neurons, decrease in the density of DA innervation in the nucleus accumbens, reduced activity-dependent DA release, and impaired motor behaviour [281]. Thus, despite
the established concept that excessive activation of glutamatergic receptors results in neurotoxicity [282], in certain cases glutamate could have the opposite effect and contribute to survival and neuroprotection [283].

Interestingly, VGLUTs may also serve a role in development and neuroprotection in DRG neurons, as suggested in a recent study showing that glutaamate release is essential to the development, maintenance, and sensory function of the piloneural mechanoreceptor, with VGLUT$_2$ being a key player [284].

9. Could VGLUTs Become Pharmacological Targets for the Control of Pain?

Throughout this review, we have highlighted the current knowledge on VGLUTs in peripheral neurons and the spinal cord, their regulation by tissue injury, and their involvement in sensation and pain. The abundance of VGLUT$_2$ in the periphery implies a fundamental role in glutamatergic physiology, even though the more discrete expression of VGLUT$_1$ and VGLUT$_3$ also suggests specific roles in select groups of DRG neurons. Data in transgenic mice, where a 50% reduction in VGLUT$_2$ [155, 240, 241, 243] or total ablation of VGLUT$_3$ [66] protein results in reduced/attenuated mechanical and cold hyperalgesia/alloodynia after peripheral nerve injury or nonvisceral inflammation, while leaving unaffected other types of sensory processing, including acute nociception and inflammatory hyperalgesia, are compelling. Based on this knowledge, pharmacological blockade (total or partial) of VGLUT activity could efficiently reduce the amount of glutamate per vesicle, affect the size of glutamatergic quanta [241, 285, 286], and thus, attenuate glutamatergic neurotransmission, both at central and/or peripheral sites, resulting in the reduction of pain.

Exogenous VGLUT inhibitors, such as Chicago sky blue 6B (CSB6B), have been shown to inhibit the loading of glutamate into synaptic vesicles upon intracerebroventricular application [287], resulting in the inhibition of the methamphetainduced hyperlocomotion and behavioural sensitization [288]. Interestingly, in an older study, Beirith et al. [289] evaluated the role of a systemically delivered CSB6B in animals receiving an intraplantar injection of glutamate and found that the use of the VGLUT inhibitor results in a considerable reduction of glutamate-induced nociception. However, the site of action of systemically applied CSB6B was not evaluated in that study, and thus, whether the inhibition of vesicular glutamate uptake occurs at peripheral nerve endings, spinal cord, supraspinal levels, or all of them remains to be established. Other exogenous compounds, including the dye Evans Blue or the Bengal Rose extract, have been described as VGLUT inhibitors and await further characterization [290, 291].

Endogenous VGLUT regulators also exist. Thus, fasting or diets with high lipidic and low glucose content (ketogenic diet), originally used to successfully reduce epileptic seizures [292], result in reduced pain and inflammation in juvenile and adult rats [292, 293]. Interestingly, the mechanisms of action proposed for ketogenic diets include decreases in the intracellular glutamatergic pool, as shown in cultured cerebellar granule neurons [294] and of glutamate uptake in synaptic vesicles by interference with the VGLUT chloride binding sites described in Section 7 [295]. However, the possible association of ketogenic diets, VGLUTs modulation, glutamate vesicular loading and pain mechanisms remain to be further established. Finally, different products of the kynurenine pathway in the metabolism of the amino acid tryptophan have been shown to exert antinociceptive roles after intraperitoneal administration in rats [296, 297], possibly through inhibition of VGLUTs activity [298].

Synthetic VGLUT inhibitors have been recently developed and their blocking action demonstrated in vitro [299, 300]. Unfortunately, these inhibitors do not discriminate between VGLUT types, and their role in vivo has yet to be determined. The development of selective VGLUT antagonists not only could help in dissecting the role of each VGLUT in in vitro and in vivo studies, but could also be therapeutically interesting, since regulation of the quantal size before fusion to the plasma membrane is emerging as an attractive approach to regulate the function of several neurotransmitters and as a tool to generate new pharmacological compounds [19, 301]. It is noteworthy that commercially available anticonvulsant agents such as gabapentin, lamotrigine, and riluzole limit glutamate release as part of their mechanisms of action and have been shown to be effective in reducing hyperalgesia in rats with neuropathy [302]. However, whether these agents act on VGLUTs to affect glutamate release is currently unknown.

The reduction of pain behaviour by topical targeting of peripheral glutamatergic mechanisms should also be considered. Thus, blockade of peripheral glutamatergic receptors emerge as an interesting therapeutic option [253, 270, 274, 303, 304], especially in view of the complex and serious CNS-driven side effects of systemically delivered glutamatergic receptor antagonists [303, 305, 306]. Likewise, inhibiting the peripheral synthesis of glutamate by targeting glutaminase bears promise [16]. In fact, glutaminase is upregulated in rat DRG neurons during inflammatory processes of the hindpaw [239], and its peripheral inhibition results in a reduction of the inflammation-induced hindpaw edema and of c-fos expression in laminae I-II of the dorsal horn of rats, as well as long-lasting analgesia [307]. Finally, and based on their abundant peripheral representation (especially for VGLUT$_2$), it is likely that challenging the activity of peripheral VGLUTs should also result in efficient modulation of glutamatergic neurotransmission.

10. Summary

In conclusion, this review has addressed various aspects relating to VGLUTs in visceral and nonvisceral DRGs, sympathetic neurons, and the spinal cord. When focusing on some of the functions of VGLUTs, the expression of VGLUT$_1$ in primary afferent nerves terminating in spinal areas such as those occupied by the dorsal nucleus of Clarke (also VGLUT$_1$-expressing) and motoneurons suggests a role in proprioception, whereas VGLUT$_2$, and to some extent
VGLUT\textsubscript{3}, exhibits a robust association to nociception and pain. Moreover, the frequent coexpression of VGLUT\textsubscript{2} and CGRP supports the idea of corelease, and this could be relevant in processes of neurogenic inflammation. The \textit{de novo} expression of VGLUT\textsubscript{3} in the LSC supports previously unexpected roles, such as sympathetic glutamatergic neurotransmission and/or survival and neuroprotection. Finally, the efficacy of the genetic deletion of VGLUT\textsubscript{3} (even if only half of what a neuron normally produces) and VGLUT\textsubscript{3} for the control of pain in rodents highlights the potential of these VGLUTs as potentially interesting targets for the development of new analgesic compounds. In such line of thought, it would be important to analyze the presence and distribution of VGLUTs in human peripheral nervous tissue and how do they react to tissue or nerve insult.

**Abbreviations**

ATF-3: Activating transcription factor, type 3  
CGRP: Calcitonin gene related peptide  
CNS: Central nervous system  
DA: Dopamine  
DRG: Dorsal root ganglion  
EAAT: Excitatory amino acid transporter  
EGFP: Enhanced green fluorescent protein  
GC: Granular cells  
IB4: Isolectin B4  
IGLEs: Intraganglionic laminar endings  
IR: Immunoreactive  
KO: Knock-out  
L: Lumbar  
Li: Like-immunoreactivity  
LSC: Lumbar sympathetic chain  
LSN: Lumbar splanchnic nerve  
MPG: Major pelvic ganglion  
Na\textsubscript{V}1.8: Voltage dependent sodium channel, type 1.8  
NGF: Nerve growth factor  
P\textsubscript{2}X\textsubscript{3}: P2X purinoceptor 3  –arachidonate  
PNS: Peripheral nervous system  
SCG: Superior cervical ganglion  
TH: Tyrosine hydroxylase  
TL: Thoracolumbar  
TRPA\textsubscript{1}: Transient receptor potential cation channel, subfamily A, member 1  
TRPV\textsubscript{1}: Transient receptor potential cation channel, subfamily V, member 1  
VGLUT: Vesicular glutamate transporter  
Y1R: Neuropeptide tyrosine receptor, type 1  
Y2R: Neuropeptide tyrosine receptor, type 2.

**Acknowledgments**

The author wishes to thank Professors Tomas Hökfelt, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; G.F. Gebhart, Director of the Pittsburgh Pain Center, University of Pittsburgh, USA; Masahiko Watanabe, Department of Anatomy, Hokkaido University School of Medicine, Sapporo, Japan; and Kim B. Seroogy, Department of Neurology, University of Cincinnati, Ohio, USA; and Drs. Carly J. McCarthy, Mariana Malet and Marcelo J. Villar, Faculty of Biomedical Sciences, Austral University, and Rebecca Seal, University of Pittsburgh, USA, for their valuable support at different stages of research on VGLUTs. The preparation of this review was supported by an IASP Early Career Research Award, an Austral University grant, and CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas).

**References**

[1] P. Marmirolli and G. Cavaletti, “The glutamatergic neurotransmission in the central nervous system,” Current Medicinal Chemistry, vol. 19, no. 9, pp. 1269–1276, 2012.

[2] A. H. Dickenson, V. Chapman, and G. M. Green, “The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord,” General Pharmacology, vol. 28, no. 5, pp. 633–638, 1997.

[3] W. D. Willis Jr. and R. E. Coggeshall, Primary Afferent Neurons and the Spinal Dorsal Horn, vol. 1, Plenum Publishers, New York, NY, USA, 2004.

[4] J. Storm-Mathisen, A. K. Leknes, A. T. Bore et al., “First visualization of glutamate and GABA in neurones by immunocytochemistry,” Nature, vol. 301, no. 5900, pp. 517–520, 1983.

[5] O. P. Ottersen and J. Storm-Mathisen, “Different neuronal localization of aspartate-like and glutamate-like immunoreactivities in the hippocampus of rat, guinea-pig and Senegalese baboon (Papio papio), with a note on the distribution of \(\gamma\)-aminobutyrate,” Neuroscience, vol. 16, no. 3, pp. 589–606, 1985.

[6] J. Storm-Mathisen and O. P. Ottersen, “Immunocytochemistry of glutamate at the synaptic level,” Journal of Histochemistry and Cytochemistry, vol. 38, no. 12, pp. 1733–1743, 1990.

[7] F. Fonnun, “Glutamate: a neurotransmitter in mammalian brain,” Journal of Neurochemistry, vol. 42, no. 1, pp. 1–11, 1984.

[8] J. H. Laake, R. Torp, and O. P. Ottersen, “Ultrastructural immunocytochemical studies as a means of distinguishing between transmitter and non-transmitter glutamate,” Biochemical Society Transactions, vol. 21, no. 1, pp. 45–49, 1993.

[9] L. H. Berghersen and V. Gunderssen, “Morphological evidence for vesicular glutamate release from astrocytes,” Neuroscience, vol. 158, no. 1, pp. 260–265, 2009.

[10] A. Wánaka, Y. Shirotani, H. Kiyama et al., “Glutamate-like immunoreactive structures in primary sensory neurons in the rat detected by a specific antiserum against glutamate,” Experimental Brain Research, vol. 65, no. 3, pp. 69–74, 1987.

[11] G. Battaglia and A. Rustioni, “Coexistence of glutamate and substance P in dorsal root ganglion neurons of the rat and monkey,” Journal of Comparative Neurology, vol. 302–312, 1988.

[12] K. N. Westlund, D. L. McNeill, and R. E. Coggeshall, “Glutamate immunoreactivity in rat dorsal root axons,” Neuroscience Letters, vol. 96, no. 1, pp. 13–17, 1989.

[13] M. A. Kai-Kai and R. Howe, “Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat,” Histochemical Journal, vol. 23, no. 4, pp. 171–179, 1991.

[14] J. R. Keast and T. M. Stephensen, “Glutamate and aspartate immunoreactivity in dorsal root ganglion cells supplying visceral and somatic targets and evidence for peripheral axonal
transport,” *Journal of Comparative Neurology*, vol. 424, no. 4, pp. 577–587, 2000.

[15] T. Kaneko, H. Akiyama, I. Nagatsu, and N. Mizuno, “Immuno-histochemical demonstration of glutaminase in catecholaminergic and serotoninergic neurons of rat brain,” *Brain Research*, vol. 507, no. 1, pp. 151–154, 1990.

[16] K. E. Miller, E. M. Hoffman, M. Sutharshan, and R. Schechter, “Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms,” *Pharmacology and Therapeutics*, vol. 130, no. 3, pp. 283–309, 2011.

[17] T. Hökfelt, O. Johansson, and M. Goldstein, “Chemical anatomy of the brain,” *Science*, vol. 225, no. 4668, pp. 1326–1334, 1984.

[18] N. C. Danbolt, “Glutamate uptake,” *Progress in Neurobiology*, vol. 65, no. 1, pp. 1–105, 2001.

[19] R. H. Edwards, “The neurotransmitter cycle and quantal size,” *Neuron*, vol. 55, no. 6, pp. 835–858, 2007.

[20] J. Broman, B. Hassel, E. Rinvik, and O. P. Ottersen, “Biochemistry and anatomy of transmitter glutamate,” in *Handbook of Chemical Neuroanatomy*, O. P. Ottersen and J. Storm-Mathisen, Eds., pp. 1–44, Elsevier, Amsterdam, The Netherlands, 2000.

[21] B. Ni, P. R. Rostek Jr., N. S. Nadi, and S. M. Paul, “Cloning and expression of a cDNA encoding a brain-specific Na+-dependent inorganic phosphate cotransporter,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 12, pp. 5607–5611, 1994.

[22] E. E. Bellocchio, R. J. Reimer, R. T. Fremeau Jr., and R. H. Edwards, “Uptake of glutamate into synaptic vesicles by an inorganic phosphate cotransporter,” *Science*, vol. 289, no. 5481, pp. 957–960, 2000.

[23] S. Takamori, J. S. Rhee, C. Rosenmund, and R. Jahn, “Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons,” *Nature*, vol. 407, no. 6801, pp. 189–194, 2000.

[24] Y. Aihara, H. Mashima, H. Onda et al., “Molecular cloning and functional identification of a novel brain-type Na+-dependent inorganic phosphate cotransporter,” *Journal of Biological Chemistry*, vol. 276, no. 39, pp. 36764–36769, 2001.

[25] R. T. Fremeau Jr., M. D. Troyer, I. Pahner et al., “The expression of vesicular glutamate transporters defines two classes of excitatory synapse,” *Neuron*, vol. 31, no. 2, pp. 247–260, 2001.

[26] M. Hayashi, M. Otsuka, R. Morimoto et al., “Differentiation-associated Na+-dependent inorganic phosphate cotransporter (DNPI) is a vesicular glutamate transporter in endocrine glutamatergic systems,” *The Journal of Biological Chemistry*, vol. 276, no. 46, pp. 43400–43406, 2001.

[27] E. Herzog, G. C. Bellenchi, C. Gras et al., “The existence of a second vesicular glutamate transporter species subpopulations of glutamatergic neurons,” *The Journal of Neuroscience*, vol. 21, no. 22, p. RC181, 2001.

[28] S. Takamori, J. S. Rhee, C. Rosenmund, and R. Jahn, “Identification of differentiation-associated brain-specific phosphate transporter as a second vesicular glutamate transporter (VGLUT2),” *The Journal of Neuroscience*, vol. 21, no. 22, p. RC182, 2001.

[29] H. Varoqui, M. K.-H. Schäfer, H. Zhu, E. Weihe, and J. D. Erickson, “Identification of the differentiation-associated Na+/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses,” *The Journal of Neuroscience*, vol. 22, no. 1, pp. 142–155, 2002.

[30] R. T. Fremeau Jr., J. Burman, T. Qureshi et al., “The identification of vesicular glutamate transporter 3 suggests novel modes of signaling by glutamate,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 22, pp. 14488–14493, 2002.

[31] C. Gras, E. Herzog, G. C. Bellenchi et al., “A third vesicular glutamate transporter expressed by cholinergic and serotoninergic neurons,” *The Journal of Neuroscience*, vol. 22, no. 13, pp. 5442–5451, 2002.

[32] M. K.-H. Schäfer, H. Varoqui, N. Defamie, E. Weihe, and J. D. Erickson, “Molecular cloning and functional identification of mouse vesicular glutamate transporter 3 and its expression in subsets of novel excitatory neurons,” *The Journal of Biological Chemistry*, vol. 277, no. 52, pp. 50734–50748, 2002.

[33] Y. Moriyama and A. Yamamoto, “Glutamatergic chemical transmission: look! here, there, and anywhere,” *The Journal of Biochemistry*, vol. 135, no. 2, pp. 155–163, 2004.

[34] S. Takamori, “VGLUTs: ‘Exciting’ times for glutamatergic research?” *Neuroscience Research*, vol. 55, no. 4, pp. 343–351, 2006.

[35] M. Liguiz-Lecznar and J. Skangiel-Kramskas, “Vesicular glutamate transporters (VGLUTs): the three musketeers of glutamatergic system,” *Acta Neurobiologica Experimentalis*, vol. 67, no. 3, pp. 207–218, 2007.

[36] Å. Wållén-Mackenzie, H. Wootz, and H. Englund, “Genetic inactivation of the vesicular glutamate transporter 2 (VGLUT2) in the mouse: what have we learnt about functional glutamatergic neurotransmission?” *Upsala Journal of Medical Sciences*, vol. 115, no. 1, pp. 11–20, 2010.

[37] P. Kitzman, “VGLUT1 and GLYT2 labeling of sacrocaudal motoneurons in the spinal cord injured spastic rat,” *Experimental Neurology*, vol. 204, no. 1, pp. 195–204, 2007.

[38] R. N. Ranson, R. M. Santer, and A. H. D. Watson, “Ageing reduces the number of vesicular glutamate transporter 2 containing immunoreactive inputs to identified rat pelvic motoneurons,” *Experimental Gerontology*, vol. 42, no. 6, pp. 506–516, 2007.

[39] I. J. Llewellyn-Smith, C. L. Martin, N. M. Fenwick, S. E. Dicarlo, H. L. Lujan, and A. M. Schreíhofer, “VGLUT1 and VGLUT2 innervation in autonomic regions of intact and transected rat spinal cord,” *Journal of Comparative Neurology*, vol. 503, no. 6, pp. 741–767, 2007.

[40] J. Zhou, N. Nannapaneni, and S. Shore, “Vesicular glutamate transporters 1 and 2 are differentially associated with auditory nerve and spinal trigeminal inputs to the cochlear nucleus,” *Journal of Comparative Neurology*, vol. 500, no. 4, pp. 777–787, 2007.

[41] H.-Y. Zhou, S.-R. Chen, H. Chen, and H.-L. Pan, “The glutamatergic nature of TRPV1-expressing neurons in the spinal dorsal horn,” *Journal of Neuroscience*, vol. 108, no. 1, pp. 305–318, 2009.

[42] E. Herzog, M. Landry, E. Buhler et al., “Expression of vesicular glutamate transporters, VGLUT1 and VGLUT2, in cholinergic spinal motoneurons,” *European Journal of Neuroscience*, vol. 20, no. 7, pp. 1752–1760, 2004.

[43] Q. Tong, J. Ma, and A. L. Kirchgessner, “Vesicular glutamate transporter 2 in the brain–gut axis,” *NeuroReport*, vol. 12, no. 18, pp. 3929–3934, 2001.
J. L. Li, K.-H. Xiong, Y.-L. Dong, F. Fujiyama, T. Kaneko, and N. Mizuno, “Vesicular glutamate transporters, VGluT1 and VGluT2, in the trigeminal ganglion neurons of the rat, with special reference to coexpression,” *Journal of Comparative Neurology*, vol. 463, no. 2, pp. 212–220, 2003.

J.-L. Li, F. Fujiyama, T. Kaneko, and N. Mizuno, “Expression of vesicular glutamate transporters, VGluT1 and VGluT2, in axon terminals of nociceptive primary afferent fibers in the superficial layers of the medullary and spinal dorsal horns of the rat,” *Journal of Comparative Neurology*, vol. 457, no. 3, pp. 236–249, 2003.

M. J. Oliveira, A. L. Oliveira, F. Hyndling, E. Olsson et al., “Cellular localization of three vesicular glutamate transporter mRNAs and proteins in rat spinal cord and dorsal root ganglia,” *Synapse*, vol. 50, no. 2, pp. 117–120, 2003.

A. J. Todd, D. I. Hughes, E. Polgár et al., “The expression of vesicular glutamate transporters VGluT1 and VGluT2 in neurochemically defined axonal populations in the rat spinal cord with emphasis on the dorsal horn,” *European Journal of Neuroscience*, vol. 17, no. 1, pp. 13–27, 2003.

F. J. Alvarez, R. M. Villalba, R. Zerda, and S. P. Schneider, “Vesicular glutamate transporters in the spinal cord, with special reference to sensory primary afferent synapses,” *Journal of Comparative Neurology*, vol. 472, no. 3, pp. 257–280, 2004.

P. R. Brumovsky, K. B. Seroogy, K. H. Lundgren, M. Watanabe, and T. Hökfelt, “Expression of vesicular glutamate transporters and peptides in corneal afferents to trigeminal nucleus caudalis,” *Journal of Comparative Neurology*, vol. 518, no. 17, pp. 3557–3569, 2010.

P. R. Brumovsky, K. B. Seroogy, K. H. Lundgren, M. Watanabe, T. Hökfelt, and G. F. Gebhart, “Some lumbar sympathetic neurons develop a glutamatergic phenotype after peripheral axotomy with a note on VGlut2-positive perineuronal baskets,” *Experimental Neurology*, vol. 230, no. 2, pp. 258–272, 2011.

P. R. Brumovsky, D. R. Robinson, J.-H. La et al., “Expression of vesicular glutamate transporters type 1 and 2 in sensory and autonomic neurons innervating the mouse colorectum,” *Journal of Comparative Neurology*, vol. 519, no. 16, pp. 3346–3366, 2011.

P. R. Brumovsky, R. P. Seal, K. H. Lundgren, K. B. Seroogy, M. Watanabe, and G. F. Gebhart, “Expression of vesicular glutamate transporters in sensory and autonomic neurons innervating the mouse bladder,” *The Journal of Urology*, vol. 189, pp. 2342–2349, 2012.

S. K. Paik, S. K. Kim, S. J. Choi, E. S. Yang, S. H. Ahn, and Y. C. Bae, “Vesicular glutamate transporters in axons that innervate the human dental pulp,” *Journal of Endodontics*, vol. 38, no. 4, pp. 470–474, 2012.

C.-Q. Yang, Y.-Y. Wei, Y.-X. Leng et al., “Vesicular glutamate transporter-3 contributes to visceral hyperalgesia induced by trichinella spiralis infection in rats,” *Digestive Diseases and Sciences*, vol. 57, pp. 865–872, 2011.

S. Lou, B. Duan, L. Vong, B. B. Lowell, and Q. Ma, “Runx1 controls terminal morphology and mechanosensitivity of VGluT3-expressing C-mechanosensitive afferents,” *The Journal of Neuroscience*, vol. 33, pp. 870–882, 2013.

R. P. Seal, X. Wang, Y. Guan et al., “Injury-induced mechanical hypersensitivity requires C-low threshold mechanoreceptors,” *Nature*, vol. 462, no. 7273, pp. 651–655, 2009.

V. Montana, Y. Ni, V. Sunjara, X. Hua, and V. Parpura, “Vesicular glutamate transporter-dependent glutamate release from astrocytes,” *The Journal of Neuroscience*, vol. 24, no. 11, pp. 2633–2642, 2004.

E. Anlauf and A. Derouiche, “Astrocytic exocytosis vesicles and glutamate: a high-resolution immunofluorescence study,” *GLIA*, vol. 49, no. 1, pp. 96–106, 2005.

Y. Ni, E. B. Malarkey, and V. Parpura, “Vesicular release of glutamate mediates bidirectional signaling between astrocytes and neurons,” *Journal of Neurochemistry*, vol. 103, no. 4, pp. 1273–1284, 2007.

L. Pawson, A. K. Pack, and S. I. Bolanowski, “Possible glutaminergic interaction between the capsule and neurite of Pacinian corpuscles,” *Somatosensory and Motor Research*, vol. 24, no. 1-2, pp. 85–95, 2007.

I. Pintelon, L. Brouns, I. de Proost, F. van Meir, J.-P. Timmermans, and D. Adriaensen, “Sensory receptors in the visceral pleura: neurochemical coding and live staining in whole mounts,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 36, no. 5, pp. 541–551, 2007.

E. Polgár, K. M. Al-Khater, S. Shehab, M. Watanabe, and A. J. Todd, “Large projection neurons in lamina I of the rat spinal cord that lack the neurokinin 1 receptor are densely innervated by VGluT2-containing axons and possess GluR4-containing AMPA receptors,” *The Journal of Neuroscience*, vol. 28, no. 49, pp. 13150–13160, 2008.

S. B. Mazzzone and A. E. McGovern, “Immunohistochemical characterization of nodose cough receptor neurons projecting to the trachea of guinea pigs,” *Cough*, vol. 4, no. 1, article 9, 2008.

D. M. Hegarty, K. Tonsfeldt, S. M. Hermes, H. Helfand, and S. A. Aicher, “Differential localization of vesicular glutamate transporters and peptides in corneal afferents to trigeminal nucleus caudalis,” *Journal of Comparative Neurology*, vol. 518, no. 17, pp. 3557–3569, 2010.

G. Gómez-Lira, M. Lamas, H. Romo-Parra, and R. Gutiérrez, “Programmed and induced phenotype of the hippocampal granule cells,” *The Journal of Neuroscience*, vol. 25, no. 30, pp. 6939–6946, 2005.

G. J. Bennett, “Animal models of pain,” in *Methods in Pain Research*, L. Kruger, Ed., pp. 67–92, CRC Press, Boca Raton, FL, USA, 2001.

D. R. Robinson and G. F. Gebhart, “Inside information: the unique features of visceral sensation,” *Molecular Interventions*, vol. 8, no. 5, pp. 242–253, 2008.
[74] S. J. Brookes, N. J. Spencer, M. Costa, and V. P. Zagorodnyuk, "Extrinsic primary afferent signalling in the gut," Nature Reviews Gastroenterology & Hepatology, vol. 10, pp. 286–296, 2013.

[75] H.-R. Berthoud and W. L. Neuhuber, "Functional and chemical anatomy of the afferent vagal system," Autonomic Neuroscience, vol. 85, no. 1–3, pp. 1–17, 2000.

[76] J. A. Christianson, R. J. Traub, and B. M. Davis, "Differences in spinal distribution and neurochemical phenotype of colonic afferents in mouse and rat," Journal of Comparative Neurology, vol. 494, no. 2, pp. 246–259, 2006.

[77] D. R. Robinson, P. A. Mcnaughton, M. L. Evans, and G. A. Hicks, "Characterization of the primary spinal afferent innervation of the mouse colon using retrograde labelling," Neurogastroenterology and Motility, vol. 16, no. 1, pp. 113–124, 2004.

[78] L. A. Blackshaw, S. J. H. Brookes, D. Grundy, and M. Schemann, "Sensory transmission in the gastrointestinal tract," Neurogastroenterology and Motility, vol. 19, no. 1, pp. 1–19, 2007.

[79] J. B. Furness, "The organisation of the autonomic nervous system: peripheral connections," Autonomic Neuroscience, vol. 130, no. 1-2, pp. 1–5, 2006.

[80] J. R. Keast, "Plasticity of pelvic autonomic ganglia and urogenital innervation," International Review of Cytology, vol. 248, pp. 141–208, 2006.

[81] G. Burnstock, "Autonomic neurotransmission: 60 years since Sir Henry Dale," Annual Review of Pharmacology and Toxicology, vol. 49, pp. 1–30, 2009.

[82] J. B. Furness, C. Jones, K. Nurgali, and N. Clerc, "Intrinsic primary afferent neurons and nerve circuits within the intestine," Progress in Neurobiology, vol. 72, no. 2, pp. 143–164, 2004.

[83] S. B. McMahon and J. V. Priestley, "Nociceptor plasticity," in The Neurobiology of Pain, S. P. Hunt and M. Koltenburg, Eds., pp. 35–64, Oxford University Press, Oxford, UK, 2005.

[84] P. R. Brumovsky, M. J. Villar, and T. Hökfelt, "Retrograde cellular changes in primary afferent and sympathetic neurons after nerve injury," in Encyclopedia of Pain, R. Schmidt and G. F. Gebhart, Eds., Springer, Berlin, Germany, 2013.

[85] E. Bergman, K. Carlsson, A. Liljeborg, E. Manders, T. Hökfelt, and B. Ulfhake, "Neuropeptides, nitric oxide synthase and GAP-43 in B4-binding and RT97 immunoreactive primary sensory neurons: normal distribution pattern and changes after peripheral nerve transection and aging," Brain Research, vol. 832, no. 1-2, pp. 63–83, 1999.

[86] M. Zwick, D. C. Molliver, J. Lindsay et al., "Transgenic mice possessing increased numbers of nociceptors do not exhibit increased behavioral sensitivity in models of inflammatory and neuropathic pain," Pain, vol. 106, no. 3, pp. 491–500, 2003.

[87] P. Brumovsky, M. J. Villar, and T. Hökfelt, "Tyrosine hydroxylase is expressed in a subpopulation of small dorsal root ganglion neurons in the adult mouse," Experimental Neurology, vol. 200, no. 1, pp. 153–165, 2006.

[88] P. Brumovsky, D. Stanic, S. Shuster, H. Herzog, M. Villar, and T. Hökfelt, "Neuropeptide Y2 receptor protein is present in peptidergic and nonpeptidergic primary sensory neurons of the mouse," Journal of Comparative Neurology, vol. 489, no. 3, pp. 328–348, 2005.

[89] M. J. Caterina, "Transient receptor potential ion channels as participants in thermosensation and thermoregulation," The American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 292, no. 1, pp. R64–R76, 2007.

[90] M. F. Jarvis, "Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain," Expert Opinion on Therapeutic Targets, vol. 7, no. 4, pp. 513–522, 2003.

[91] S. D. Dib-Hajj, T. R. Cummins, J. A. Black, and S. G. Waxman, "Sodium channels in normal and pathological pain," Annual Review of Neuroscience, vol. 33, pp. 325–347, 2010.

[92] G. Burnstock and J. N. Wood, "Purinergic receptors: their role in nociception and primary afferent neurotransmission," Current Opinion in Neurobiology, vol. 6, no. 4, pp. 526–532, 1996.

[93] T. Hökfelt, X. Zhang, Z. Q. Xu et al., "Cellular and synaptic mechanisms in transition of pain from acute to chronic," in Proceedings of the 8th World Congress on Pain, Progress in Pain Research and Management, T. S. Jensen, J. A. Turner, and Z. Wiesenfeld-Hallin, Eds., pp. 133–153, IASP Press, Seattle, Wash, USA, 1997.

[94] X. J. Xu and Z. Wiesenfeld-Hallin, "Novel modulators in pain," in The Pharmacology of Pain, Handbook of Experimental Neurology, A. H. Dickenson and J. M. Hesson, Eds., pp. 211–234, Springer, Berlin, Germany, 1997.

[95] W. C. de Groat, M. Kawatani, M. B. Houston, M. Rutigliano, and S. Erdman, "Identification of neuropeptides in afferent pathways to the pelvic visera of the cat," in Organization of the Autonomic Nervous System: Central and Peripheral Mechanisms. Neurology and Neurobiology, J. Ciriello, F. Calaresu I, Renaud, and C. Polosa, Eds., pp. 81–90, A.R. Liss, New York, NY, USA, 1987.

[96] J. R. Keast and W. C. de Groat, "Segmental distribution and peptide content of primary afferent neurons innervating the urogenital organs and colon of male rats," Journal of Comparative Neurology, vol. 319, no. 4, pp. 615–623, 1992.

[97] D. L. H. Bennett, N. Dmitrieva, J. V. Priestley, D. Clary, and S. B. McMahon, "trkA, CGRP and IB4 expression in retrogradely labelled cutaneous and visceral primary sensory neurons in the rat," Neuroscience Letters, vol. 206, no. 1, pp. 33–36, 1996.

[98] H. F. Wang, P. Shortland, M. J. Park, and G. Grant, "Retrograde and transganglionic transport of horseradish peroxidase-conjugated cholera toxin B subunit, wheatgerm agglutinin and isoleucin B4 from Griffonia simplicifolia I in primary afferent neurons innervating the rat urinary bladder," Neuroscience, vol. 87, no. 1, pp. 275–288, 1998.

[99] P. R. Brumovsky, J. H. La, C. J. McCarthy, T. Hökfelt, and G. F. Gebhart, "Dorsal root ganglion neurons innervating pelvic organs in the mouse express tyrosine hydroxylase," Neuroscience, vol. 223, pp. 77–91, 2012.

[100] L.-G. Elfvin, B. Lindh, and T. Hökfelt, "The chemical neuroanatomy of sympathetic ganglia," Annual Review of Neuroscience, vol. 16, pp. 471–507, 1993.

[101] R. E. Zigmond and Y. Sun, "Regulation of neuropeptide expression in sympathetic neurons. Paracrine and retrograde influences," Annals of the New York Academy of Sciences, vol. 814, pp. 181–197, 1997.

[102] M. Landry, K. Holmberg, X. Zhang, and T. Hökfelt, "Effect of axotomy on expression of NPY, galanin, and NPY Y1 and Y2 receptors in dorsal root ganglia and the superior cervical ganglion studied with double-labeling in situ hybridization and immunohistochemistry," Experimental Neurology, vol. 162, no. 2, pp. 361–384, 2000.

[103] M. Costa and S. H. Brookes, "Architecture of enteric neural circuits involved in intestinal motility," European Review for Medical and Pharmacological Sciences, vol. 12, no. 1, pp. 3–19, 2008.
[104] B. Rexed, “The cytoarchitectonic organization of the spinal cord in the cat,” The Journal of Comparative Neurology, vol. 96, no. 3, pp. 414–495, 1952.

[105] T. J. Grudt and E. R. Perl, “Correlations between neuronal morphology and electro-physiological features in the rodent superficial dorsal horn,” Journal of Physiology, vol. 540, no. 1, pp. 189–207, 2002.

[106] S. A. Prescott and Y. De Koninck, “Four cell types with distinctive membrane properties and morphologies in lamina I of the spinal dorsal horn of the adult rat,” Journal of Physiology, vol. 539, no. 3, pp. 817–836, 2002.

[107] R. Morris, O. Cheunsuang, A. Stewart, and D. Maxwell, “Spinal dorsal horn neurone targets for nociceptive primary afferents: do single neurone morphological characteristics suggest how nociceptive information is processed at the spinal level,” Brain Research Reviews, vol. 46, no. 2, pp. 173–190, 2004.

[108] P. Burgess and E. R. Perl, “Cutaneous mecanoreceptors and nociceptors,” in Cutaneous Mechanoreceptors and Nociceptors, A. Iggo, Ed., pp. 29–78, Springer, Berlin, Germany, 1973.

[109] M. Zimmermann, “Neurophysiology of nociception,” in Neurophysiology of Nociception, R. Porter, Ed., pp. 179–221, University Park, Baltimore, Md, USA, 1976.

[110] A. R. Light and E. R. Perl, “Spinal termination of functionally identified primary afferent fibers with slowly conducting myelinated fibers,” Journal of Comparative Neurology, vol. 186, no. 2, pp. 133–150, 1979.

[111] S. Gobel, W. M. Falls, and E. Humphrey, “Morphology and synaptic connections of ultraneous primary axons in lamina I of the spinal dorsal horn: candidates for the terminal axonal arbors of primary neurons with unmyelinated (C) axons,” The Journal of Neuroscience, vol. 1, no. 10, pp. 1163–1179, 1981.

[112] A. D. Craig and S. Mense, “The distribution of afferent fibers from the gastrocnemius-soleus muscle in the dorsal horn of the cat, as revealed by the transport of horseradish peroxidase,” Neuroscience Letters, vol. 41, no. 3, pp. 233–238, 1983.

[113] A. D. Craig, B. Heppelmann, and H.-G. Schaible, “The projection of the medial and posterior articular nerves of the cat’s knee to the spinal cord,” Journal of Comparative Neurology, vol. 276, no. 2, pp. 279–288, 1988.

[114] C. Morgan, I. Nadelhaft, and W. C. de Groat, “The distribution of visceral primary afferents from the pelvic nerve to Lissauer’s tract and the spinal gray matter and its relationship to the sacral parasympathetic nucleus,” Journal of Comparative Neurology, vol. 201, no. 3, pp. 415–440, 1981.

[115] J. Ciriello and F. R. Calaresu, “Central projections of afferent primary fibers to the rat spinal cord: an anterograde transport study of horseradish peroxidase,” Journal of the Autonomic Nervous System, vol. 8, no. 3, pp. 273–285, 1983.

[116] I. Nadelhaft, J. Roppolo, C. Morgan, and W. C. de Groat, “Parasympathetic preganglionic neurons and visceral primary afferents in monkey sacral spinal cord revealed following application of horseradish peroxidase to pelvic nerve,” Journal of Comparative Neurology, vol. 216, no. 1, pp. 36–52, 1983.

[117] S. Gobel and W. M. Falls, “Anatomical observations of horseradish peroxidase–filled terminal primary axonal arborizations in layer II of the substantia gelatinosa of Rolando,” Brain Research, vol. 175, no. 2, pp. 335–340, 1979.

[118] Y. Sugiura, N. Terui, and Y. Hosoya, “Difference in distribution of central terminals between visceral and somatic unmyelinated (C) primary afferent fibers,” Journal of Neurophysiology, vol. 62, no. 4, pp. 834–840, 1989.

[119] Y. Sugiura, C. L. Lee, and E. R. Perl, “Central projections of identified, unmyelinated (C) afferent fibers innervating mammalian skin,” Science, vol. 234, no. 4774, pp. 358–361, 1986.

[120] F. Cruz, D. Lima, W. Ziegglansberger, and A. Coimbra, “Fine structure and synaptic architecture of HRP-labelled primary afferent terminations in lamina II of the rat dorsal horn,” Journal of Comparative Neurology, vol. 305, no. 1, pp. 3–16, 1991.

[121] J. I. Nagy and S. P. Hunt, “The termination of primary afferents within the rat dorsal horn: evidence for rearrangement following capsaicin treatment,” Journal of Comparative Neurology, vol. 218, no. 2, pp. 145–158, 1983.

[122] F. Cruz, D. Lima, and A. Coimbra, “Several morphological types of terminal arborizations of primary afferents in laminae I–II of the rat spinal cord, as shown after HRP labeling and Golgi impregnation,” Journal of Comparative Neurology, vol. 261, no. 2, pp. 221–236, 1987.

[123] C. J. Woolf, “Central terminations of cutaneous mechanoreceptive afferents in the rat lumbar spinal cord,” Journal of Comparative Neurology, vol. 261, no. 1, pp. 105–119, 1987.

[124] P. Shortland, C. J. Woolf, and M. Fitzgerald, “Morphology and somatotopic organization of the central terminals of hindlimb hair follicle afferents in the rat lumbar spinal cord,” Journal of Comparative Neurology, vol. 289, no. 3, pp. 416–433, 1989.

[125] P. Shortland and C. J. Woolf, “Morphology and somatotopy of the central arborizations of rapidly adapting glabrous skin afferents in the rat lumbar spinal cord,” Journal of Comparative Neurology, vol. 329, no. 4, pp. 491–511, 1993.

[126] S. Ramón y Cajal, “General principles, spinal cord, spinal ganglia, medulla and pons,” in Histology of the Nervous System of Man and Vertebrates, pp. 247–249, Oxford University Press, Oxford, UK, 1899.

[127] A. Brown, Organization in the Spinal Cord: The Anatomy and Physiology of Identified Neurons, Springer, Verlin, France, 1981.

[128] H. J. Ralston III and D. D. Ralston, “The distribution of dorsal root axons to laminae IV, V, and VI of the macaque spinal cord: a quantitative electron microscopic study,” Journal of Comparative Neurology, vol. 212, no. 4, pp. 435–448, 1982.

[129] F. Cervero and L. A. Connell, “Distribution of somatic and visceral primary afferent fibres within the thoracic spinal cord of the cat,” Journal of Comparative Neurology, vol. 230, no. 1, pp. 88–98, 1984.

[130] C. LaMotte, “Distribution of the tract of Lissauer and the dorsal root fibers in the primate spinal cord,” Journal of Comparative Neurology, vol. 172, no. 3, pp. 529–561, 1977.

[131] C. Molander and G. Grant, “Laminar distribution and somatotopic organization of primary afferent fibers from hindlimb nerves in the dorsal horn. A study by transganglionic transport of horseradish peroxidase in the rat,” Neuroscience, vol. 19, no. 1, pp. 297–312, 1986.

[132] H. F. Wang, B. Robertson, and G. Grant, “Anterograde transport of horseradish-peroxidase conjugated isoelectin B4 from Griffonia simplicifolia I in spinal primary sensory neurons of the rat,” Brain Research, vol. 811, no. 1-2, pp. 34–39, 1998.

[133] W. Neuhuber, “The central projections of visceral primary afferent neurons of the inferior mesenteric plexus and hypogastric nerve and the location of the related sensory and preganglionic sympathetic cell bodies in the rat,” Anatomy and Embryology, vol. 164, no. 3, pp. 413–425, 1982.

[134] I. Nadelhaft and A. M. Booth, “The location and morphology of preganglionic neurons and the distribution of visceral afferents from the rat pelvic nerve: a horseradish peroxidase study,”
J. P. Lund, S. Sadeghi, T. Athanassiadis et al., “Assessment of the potential role of muscle spindle mechanoreceptor afferents in chronic muscle pain in the rat masseter muscle,” PloS ONE, vol. 5, no. 6, Article ID e11131, 2010.

I. Brouns, I. Pintelon, J. van Genechten, I. de Proost, J.-P. Timmermans, and D. Adriaensen, “Vesicular glutamate transporter 2 is expressed in different nerve fibre populations that selectively contact pulmonary neuroepithelial bodies,” Histochemistry and Cell Biology, vol. 121, no. 1, pp. 1–12, 2004.

M. Ludwig, Dendritic Neurotransmitter Release, Springer, New York, NY, USA, 2004.

Y. M. Ulrich-Lai, C. M. Flores, C. A. Harding-Rose, H. E. Goodis, and K. M. Hargreaves, “Capsaicin-evoked release of immunoreactive calcitonin gene-related peptide from rat trigeminal ganglion: Evidence for intraganglionic neurotransmission,” Pain, vol. 91, no. 3, pp. 219–226, 2001.

S. Thalakoti, V. Y. Patil, S. Damodaram et al., “Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology,” Headache, vol. 47, no. 7, pp. 1008–1023, 2007.

X. Zhang, Y. Chen, C. Wang, and L.-Y. M. Huang, “Neuronal somatic ATP release triggers neuron-satellite glial cell communication in dorsal root ganglia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 23, pp. 9864–9869, 2007.

J. M. Bráz, L. Ackerman, and A. I. Basbaum, “Sciatic nerve transection triggers release and intercellular transfer of a genetically expressed macromolecular tracer in dorsal root ganglia,” Journal of Comparative Neurology, vol. 519, no. 13, pp. 2648–2657, 2011.

B. Mackenzie, A. C. Illing, M. E. K. Morris, H. Varoqui, and J. D. Erickson, “Analysis of a vesicular glutamate transporter (VGLUT2) supports a cell-leakage mode in addition to vesicular packaging,” Neurochemical Research, vol. 33, no. 2, pp. 238–247, 2008.

K. E. Miller, V. D. Douglas, and T. Kaneko, “Glutaminase immunoreactive neurons in the rat dorsal root ganglion contain calcitonin gene-related peptide (CGRP),” Neuroscience Letters, vol. 160, no. 1, pp. 113–116, 1993.

S. de Biasi and A. Rustioni, “Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 20, pp. 7820–7824, 1988.

S. E. J. Hwang, A. Burette, A. Rustioni, and J. G. Valtschanoff, “Vanilloid receptor VR1-positive primary afferents are glutamatergic and contact spinal neurons that co-express neurokinin receptor NK1 and glutamate receptors,” Journal of Neurocytology, vol. 33, no. 3, pp. 321–329, 2004.

M. C. Lagerström, K. Rogoz, B. Abrahamsen et al., “VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch,” Neuron, vol. 68, no. 3, pp. 529–542, 2010.

T. Kaneko and F. Fujiyama, “Complementary distribution of vesicular glutamate transporters in the central nervous system,” Neuroscience Research, vol. 42, no. 4, pp. 243–250, 2002.

J.-L. Boulland, T. Qureshi, R. P. Seal et al., “Expression of the vesicular glutamate transporters during development indicates the widespread corelease of multiple neurotransmitters,” Journal of Comparative Neurology, vol. 480, no. 3, pp. 264–280, 2004.

R. T. Fremeau Jr., K. Kam, Y. Qureshi et al., “Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites,” Science, vol. 304, no. 5678, pp. 1815–1819, 2004.

R. T. Fremeau Jr., S. Voglmaier, R. P. Seal, and R. H. Edwards, “VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate,” Trends in Neurosciences, vol. 27, no. 2, pp. 98–103, 2004.

J. S. Dittman and W. G. Regehr, “Calcium dependence and recovery kinetics of presynaptic depression at the climbing fiber to Purkinje cell synapse,” The Journal of Neuroscience, vol. 18, no. 16, pp. 6147–6162, 1998.

M. Raab and W. L. Neuhuber, “Vesicular glutamate transporter 2 immunoreactivity in putative vagal mechanosensor terminals of mouse and rat esophagus: Indication of a local effector function?” Cell and Tissue Research, vol. 312, no. 2, pp. 141–148, 2003.

M. Raab and W. L. Neuhuber, “Number and distribution of intraganglionic laminar endings in the mouse esophagus as demonstrated with two different immunohistochemical markers,” Journal of Histochemistry and Cytochemistry, vol. 53, no. 8, pp. 1023–1031, 2005.
aspects on possible function," in *Neural Peptides and Neuronal Communication*, E. Costa and M. Trabucchi, Eds., pp. 25–36, Raven Press, New York, NY, USA, 1980.

[194] M. R. Matthews and A. C. Cuello, “The origin and possible significance of substance P immunoreactive networks in the prevertebral ganglia and related structures in the guinea-pig,” *Philosophical Transactions of the Royal Society of London B*, vol. 306, no. 1128, pp. 247–276, 1984.

[195] J. Aioun and O. Rampin, “Anatomical evidence for glutamatergic transmission in primary sensory neurons and onto postganglionic neurons controlling penile erection in rats: an ultrastructural study with neuronal tracing and immunocytochemistry,” *Cell and Tissue Research*, vol. 323, no. 3, pp. 359–375, 2006.

[196] G. B. Luckensmeyer and J. R. Keast, “Immunohistochemical characterisation of visceralfugal neurons projecting to the inferior mesenteric and major pelvic ganglia in the male rat,” *Journal of the Autonomic Nervous System*, vol. 61, no. 1, pp. 6–16, 1996.

[197] T. J. Hibberd, V. P. Zagorodnyuk, N. J. Spencer, and S. J. Brookes, “Identification and mechanosensitivity of visceralfugal neurons,” *Neuroscience*, vol. 225, pp. 118–129, 2012.

[198] S. M. Miller and J. H. Szurszewski, “Relationship between colonic motility and cholinergic mechanosensory afferent synaptic input to mouse superior mesenteric ganglion,” *Neurogastroenterology and Motility*, vol. 14, no. 4, pp. 339–348, 2002.

[199] A. L. Kirchgessner, M.-T. Liu, and F. Alcantara, “Excitotoxicity in the enteric nervous system,” *The Journal of Neuroscience*, vol. 17, no. 22, pp. 8804–8816, 1997.

[200] L. H. Tsai, W. Tsai, and J.-Y. Wu, “Effect of L-glutamic acid on acid secretion and immunohistochemical localization of glutamatergic neurons in the rat stomach,” *The Journal of Neuroscience Research*, vol. 38, no. 2, pp. 188–195, 1994.

[201] C. Giaroni, E. Zanetti, A. M. Chiarravalli et al., “Evidence for a glutamatergic modulation of the cholinergic function in the human enteric nervous system via NMDA receptors,” *European Journal of Pharmacology*, vol. 476, no. 1-2, pp. 63–69, 2003.

[202] J. W. Wiley, Y. Lu, and C. Owyang, “Evidence for a glutamatergic neural pathway in the myenteric plexus,” *The American Journal of Physiology: Gastrointestinal and Liver Physiology*, vol. 261, no. 4, pp. G693–G700, 1991.

[203] M. Šínský and J. Donnerer, “Evidence for a neurotransmitter role of glutamate in guinea pig myenteric plexus neurons,” *Neuroscience Letters*, vol. 258, no. 2, pp. 109–112, 1998.

[204] A. L. Kirchgessner, “Glutamate in the enteric nervous system,” *Current Opinion in Pharmacology*, vol. 1, no. 6, pp. 591–596, 2001.

[205] N. Linke, N. Bodi, B. E. Resch, E. Fekete, and M. Bagyanszki, “Developmental pattern of three vesicular glutamate transporters in the myenteric plexus of the human fetal small intestine,” *Histology and Histopathology*, vol. 23, no. 7–9, pp. 979–986, 2008.

[206] X. Zhang, D. A. Dagerlind, L. Bao, R. R. Ji, J. M. Lundberg, and T. Hökfelt, “Increased expression of galanin in the rat superior cervical ganglion after pre- and postganglionic nerve lesions,” *Experimental Neurology*, vol. 127, no. 1, pp. 9–22, 1994.

[207] M. Costigan, K. Befort, L. Karchewski et al., “Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury,” *BMC Neuroscience*, vol. 3, article 16, 2002.

[208] H.-S. Xiao, Q.-H. Huang, F.-X. Zhang et al., “Identification of gene expression profile of dorsal root ganglion in the rat peripheral axotomy model of neuropathic pain,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 12, pp. 8360–8365, 2002.

[209] X. Navarro, “Chapter 27: neural plasticity after nerve injury and regeneration,” *International Review of Neurobiology*, vol. 87, pp. 483–505, 2009.

[210] X. Zhang, Z.-Q. Xu, T.-J. Shi et al., “Regulation of expression of galanin and galanin receptors in dorsal root ganglia and spinal cord after axotomy and inflammation,” *Annals of the New York Academy of Sciences*, vol. 863, pp. 402–413, 1998.

[211] K. Ren, S. I. Novikova, F. He, R. Dubner, and M. S. Lidow, “Neonatal local noxious insult affects gene expression in the spinal dorsal horn of adult rats,” *Molecular Pain*, vol. 1, article 27, 2005.

[212] J. A. Christianson, K. Bielefeldt, C. Altier et al., “Development, plasticity and modulation of visceral afferents,” *Brain Research Reviews*, vol. 60, no. 1, pp. 171–186, 2009.

[213] W. M. Al-Ghoul, G. L. Volsi, R. J. Weinberg, and A. Rustioni, “Glutamate immunocytochemistry in the dorsal horn after injury or stimulation of the sciatric nerve of rats,” *Brain Research Bulletin*, vol. 30, no. 3–4, pp. 453–459, 1993.

[214] D. I. Hughes, E. Polgár, S. A. S. Shehab, and A. J. Todd, “Peripheral axotomy induces depletion of the vesicular glutamate transporter VGLUT1 in central terminals of myelinated afferent fibres in the rat spinal cord,” *Brain Research*, vol. 1017, no. 1–2, pp. 69–76, 2004.

[215] P. R. Brumovsky, E. Bergman, H.-X. Liu, T. Hökfelt, and M. J. Villar, “Effect of a graded single constriction of the rat sciatic nerve on pain behavior and expression of immunoreactive NPY and NPY Y1 receptor in DRG neurons and spinal cord,” *Brain Research*, vol. 1006, no. 1, pp. 87–99, 2004.

[216] F. A. Chaudhry, J.-L. Boulland, M. Jenstad, M. K. L. Bredahl, and R. H. Edwards, “Pharmacology of neurotransmitter transport into secretory vesicles,” *Handbook of Experimental Pharmacology*, vol. 184, pp. 77–106, 2008.

[217] D. E. Heatherton, “Intercellular glutamate signaling in the nervous system and beyond,” *ACS Chemical Neuroscience*, vol. 1, no. 1, pp. 4–12, 2010.

[218] B. Lindh, M. Risling, S. Remahl, L. Terenius, and T. Hökfelt, “Peptide-immunoreactive neurons and nerve fibres in lumbosacral sympathetic ganglia: Selective elimination of a pathway-specific expression of immunoreactivities following sciatic nerve resection in kittens,” *Neuroscience*, vol. 55, no. 2, pp. 545–562, 1993.

[219] T. B. Cheah and L. B. Geffen, “Effects of axonal injury on norepinephrine, tyrosine hydroxylase and monoamine oxidase levels in sympathetic ganglia,” *Journal of Neurobiology*, vol. 4, no. 5, pp. 443–452, 1973.

[220] Y. Sun and R. E. Zigmond, “Involvement of leukemia inhibitory factor in the increases in galanin and vasoactive intestinal peptide mRNA and the decreases in neuropeptide Y and tyrosine hydroxylase mRNA in sympathetic neurons after axotomy,” *Journal of Neurochemistry*, vol. 67, no. 4, pp. 1751–1760, 1996.

[221] M. S. Rao, Y. Sun, U. Vaidyanathan, S. C. Landis, and R. E. Zigmond, “Regulation of substance P is similar to that of vasoactive intestinal peptide after axotomy or explantation of the rat superior cervical ganglion,” *Journal of Neurobiology*, vol. 24, no. 5, pp. 571–580, 1993.

[222] C. Skobowiat, J. Calka, and M. Majewski, “Axotomy induced changes in neuronal plasticity of sympathetic chain ganglia (SChG) neurons supplying descending colon in the pig,” *Experimental and Molecular Pathology*, vol. 90, no. 1, pp. 13–18, 2011.
[223] D. Sulzer, M. P. Joyce, L. Lin et al., "Dopamine neurons make glutamateergic synapses in vitro," *The Journal of Neuroscience*, vol. 18, pp. 4588–4602, 1998.

[224] A. Kawasaki, K. Hoshi, M. Kawano, H. Nagami, H. Yoshikawa, and S. Hisano, "Up-regulation of VGLUT2 expression in hypothalamic-neurohypophysial neurons of the rat following osmotic challenge," *European Journal of Neuroscience*, vol. 22, no. 3, pp. 672–680, 2005.

[225] T. Yamaguchi, W. Sheen, and M. Morales, "Glutamatergic neurons are present in the rat ventral tegmental area," *European Journal of Neuroscience*, vol. 25, no. 1, pp. 106–118, 2007.

[226] R. L. Stornetta, C. P. Sevigny, A. M. Schreihofer, D. L. Rosin, and P. G. Guyenet, "Vesicular glutamate transporter DNPI/VGLUT2 is expressed by both C1 adrenergic and nonamnergic presynaptic vasomotor neurons of the rat medulla," *Journal of Comparative Neurology*, vol. 444, no. 3, pp. 207–220, 2002.

[227] R. L. Stornetta, C. P. Sevigny, and P. G. Guyenet, "Vesicular glutamate transporter DNPI/VGLUT2 mRNA is present in CR1 and several other groups of brainstem catecholaminergic neurons," *Journal of Comparative Neurology*, vol. 444, no. 3, pp. 191–206, 2002.

[228] M. Kawano, A. Kawasaki, H. Sakata-Haga et al., "Particular subpopulations of midbrain and hypothalamic dopamine neurons express vesicular glutamate transporter 2 in the rat brain," *Journal of Comparative Neurology*, vol. 498, no. 5, pp. 581–592, 2006.

[229] U. Ernsberger and H. Rohrer, "Development of the cholinergic neurotransmitter phenotype in postganglionic sympathetic neurons," *Cell and Tissue Research*, vol. 297, no. 3, pp. 339–361, 1999.

[230] S. M. Wojcik, J. S. Rhee, E. Herzog et al., "An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 18, pp. 7158–7163, 2004.

[231] N. R. Wilson, J. Kang, E. V. Hueske et al., "Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1," *The Journal of Neuroscience*, vol. 25, no. 26, pp. 6221–6234, 2005.

[232] R. W. Daniels, C. A. Collins, K. Chen, M. V. Gelfand, D. E. Featherstone, and A. DiAntonio, "A single vesicular glutamate transporter is sufficient to fill a synaptic vesicle," *Neuron*, vol. 49, no. 1, pp. 11–16, 2006.

[233] S. E. Kapadia and C. C. LaMotte, "Deafferentation-induced alterations in the rat dorsal horn: I. Comparison of peripheral nerve injury vs. rhizotomy effects on presynaptic, postsynaptic and glial processes," *Journal of Comparative Neurology*, vol. 266, no. 2, pp. 183–197, 1987.

[234] X. Zhang, A. J. Bean, Z. Wiesenfeld-Hallin, X.-J. Xu, and T. Hökfelt, "Ultrastructural studies on peptides in the dorsal horn of the rat spinal cord - III. Effects of peripheral axotomy with special reference to galanin," *Neuroscience*, vol. 64, no. 4, pp. 893–915, 1995.

[235] H. Fei, A. Grygoruk, E. S. Brooks, A. Chen, and D. E. Krantz, " Trafficking of vesicular neurotransmitter transporters," *Traffic*, vol. 9, no. 9, pp. 1425–1436, 2008.

[236] M. S. Santos, H. Li, and S. M. Voglmaier, "Synaptic vesicle trafficking at the glutamate synapse;" *Neuroscience*, vol. 158, no. 1, pp. 189–203, 2009.

[237] S. Schenck, S. M. Wojcik, N. Brose, and S. Takamori, "A chloride conductance in VGLUT1 underlies maximal glutamate loading into synaptic vesicles," *Nature Neuroscience*, vol. 12, no. 2, pp. 156–162, 2009.

[238] S. Karunanithi, L. Marin, K. Wong, and H. L. Atwood, "Quantal size and variation determined by vesicle size in normal and mutant Drosophila glutamatergic synapses," *The Journal of Neuroscience*, vol. 22, no. 23, pp. 10267–10276, 2002.

[239] K. E. Miller, J. C. Balbas, R. L. Benton et al., "Glutaminase immunoreactivity and enzyme activity is increased in the rat dorsal root ganglion following peripheral inflammation," *Pain Research and Treatment*, vol. 2012, Article ID 414697, 9 pages, 2012.

[240] S. Leo, D. Moechars, Z. Callaerts-Vegh, R. D’Hooge, and T. Meert, "Impairment of VGLUT2 but not VGLUT1 signaling reduces neuropathy-induced hypersensitivity," *European Journal of Pain*, vol. 13, no. 10, pp. 1008–1017, 2009.

[241] D. Moechars, M. C. Weston, S. Leo et al., "Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain," *The Journal of Neuroscience*, vol. 26, no. 46, pp. 12055–12066, 2006.

[242] G. Grant and B. Robertson, "Primary afferent projections to the spinal cord," in *The Rat Nervous System*, G. Paxinos, Ed., pp. II2–120, Elsevier Academic Press, London, UK, 2004.

[243] M. C. Lagerström, K. Rogoz, B. Abrahamsen et al., "A sensory subpopulation depends on vesicular glutamate transporter 2 for mechanical pain, and together with substance P, inflammatory pain," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 14, pp. 5789–5794, 2011.

[244] Y. Liu, O. Abdel Samad, L. Zhang et al., "VGLUT2-dependent glutamate release from nociceptors is required to sense pain and suppress itch," *Neuron*, vol. 68, no. 3, pp. 543–556, 2010.

[245] F. Lallemend and P. Ernfors, "Molecular interactions underlying the specification of sensory neurons," *Trends in Neurosciences*, vol. 35, no. 6, pp. 373–381, 2012.

[246] J. deGroot, S. Zhou, and S. M. Carlton, "Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation," *NeuroReport*, vol. II, no. 3, pp. 497–502, 2000.

[247] S. M. Carlton, G. L. Hargett, and R. E. Coggeshall, "Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin," *Neuroscience Letters*, vol. 197, no. 1, pp. 25–28, 1995.

[248] D. L. Jackson, C. B. Graff, J. D. Richardson, and K. M. Hargreaves, "Glutamate participates in the peripheral modulation of thermal hyperalgesia in rats," *European Journal of Pharmacology*, vol. 284, no. 3, pp. 321–325, 1995.

[249] Y.-L. Tian, Y. Guo, D.-Y. Cao, Q. Zhang, H.-S. Wang, and Y. Zhao, "Local application of morphine suppresses glutamate-evoked activities of C and Aδ afferent fibers in rat hairy skin," *Brain Research*, vol. 1059, no. 1, pp. 28–34, 2005.

[250] K. Sato, H. Kiyama, H. T. Park, and M. Tobiama, "AMPA, KA and NMDA receptors are expressed in the rat DRG neurons," *NeuroReport*, vol. 4, no. 11, pp. 1263–1265, 1993.

[251] M. Tachibana, R. J. Wenthold, H. Morioka, and R. S. Petralia, "Light and electron microscopic immunocytochemical localization of AMPA- selective glutamate receptors in the rat spinal cord;" *Journal of Comparative Neurology*, vol. 344, no. 3, pp. 431–454, 1994.

[252] H. Ohishi, S. Nomura, Y.-Q. Ding et al., "Presynaptic localization of a metabotropic glutamate receptor, mGluR7, in the primary afferent neurons: an immunohistochemical study in the rat," *Neuroscience Letters*, vol. 202, no. 1-2, pp. 85–88, 1995.

[253] S. M. Carlton, "Peripheral excitatory amino acids," *Current Opinion in Pharmacology*, vol. 1, no. 1, pp. 52–56, 2001.
P. J. Kammere and S. R. Ikeda, “Metabotropic glutamate receptors on peripheral primary afferent fibers: their role in nociception,” *Brain Research*, vol. 913, no. 1, pp. 18–26, 2001.

V. V. Chaban, “Visceral sensory neurons that innervate both uterus and colon express nociceptive TRPV1 and P2X3 receptors in rats,” *Ethnology and Disease*, vol. 18, no. 2, pp. S2–S4, 2008.

T. Sugiuira, K. Bielefeldt, and G. F. Gebhart, “Mouse colon sensory neurons detect extracellular acids via TRPV1,” *The American Journal of Physiology: Cell Physiology*, vol. 292, no. 5, pp. C1768–C1774, 2007.

K. Wirkner, B. Sperlagh, and P. Illes, “P2X3 receptor involvement in pain states,” *Molecular Neurobiology*, vol. 36, no. 2, pp. 165–183, 2007.

M. Shinoda, B. Feng, and G. F. Gebhart, “Peripheral and central P2X3 receptor contributions to colonic mechanosensitivity and hypersensitivity in the mouse,” *Gastroenterology*, vol. 137, no. 6, pp. 2096–2104, 2009.

G. Burnstock, “Purinergic mechanosensory transduction and visceral pain,” *Molecular Pain*, vol. 5, p. 69, 2009.

J. M. A. Laird, V. Souslova, J. N. Wood, and F. Cervero, “Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice,” *The Journal of Neuroscience*, vol. 22, no. 19, pp. 8352–8356, 2002.

W. Jänig and R. Baron, “Complex regional pain syndrome: mystery explained?” *Lancet Neurology*, vol. 2, no. 11, pp. 687–697, 2003.

G. F. Gibbs, P. D. Drummond, P. M. Finch, and J. K. Phillips, “Unravelling the pathophysiology of complex regional pain syndrome: focus on sympathetically maintained pain,” *Clinical and Experimental Pharmacology and Physiology*, vol. 35, no. 7, pp. 717–724, 2008.

R. Shigemoto, H. Ohishi, S. Nakaniishi, and N. Mizuno, “Expression of the mRNA for the rat NMDA receptor (NMDARI) in the sensory and autonomic ganglion neurons,” *Neuroscience Letters*, vol. 144, no. 1-2, pp. 229–232, 1992.

P. J. Kammersmeier and S. R. Ikeda, “Metabotropic glutamate receptor expression in the rat superior cervical ganglion,” *Neuroscience Letters*, vol. 330, no. 3, pp. 260–264, 2002.

H. Kiyama, K. Sato, T. Kuba, and M. Tohyama, “Sympathetic and parasympathetic ganglia express non-NMDA type glutamate receptors: distinct receptor subunit composition in the principle and SIF cells,” *Molecular Brain Research*, vol. 19, no. 4, pp. 345–348, 1993.

S. M. Carlton, K. Chung, Z. Ding, and R. E. Coggleshall, “Glutamate receptors on postganglionic sympathetic axons,” *Neuroscience*, vol. 83, no. 2, pp. 601–605, 1998.

J. A. McRoberts, S. V. Coutinho, J. C. G. Marvizón et al., “Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats,” *Gastroenterology*, vol. 120, no. 7, pp. 1737–1748, 2001.

R. L. Young, A. J. Page, T. A. O’Donnell, N. J. Cooper, and L. A. Blackshaw, “Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5,” *The American Journal of Physiology: Gastrointestinal and Liver Physiology*, vol. 292, no. 2, pp. G501–G511, 2007.

L. A. Blackshaw, A. J. Page, and R. L. Young, “Metabotropic glutamate receptors as novel therapeutic targets on visceral sensory pathways,” *Frontiers in Neuroscience*, vol. 5, p. 40, 2011.

M. Julio-Pieber, R. M. O’Connor, T. G. Dinan, and J. E. Cryan, “Regulation of the brain-gut axis by group III metabotropic glutamate receptors,” *European Journal of Pharmacology*, vol. 698, pp. 19–30, 2013.

J. C. G. Marvizón, J. A. McRoberts, H. S. Ennes et al., “Two N-methyl-D-aspartate receptors in rat dorsal root ganglia with different subunit composition and localization,” *Journal of Comparative Neurology*, vol. 446, no. 4, pp. 325–341, 2002.

S. Lucifora, H. H. Willcockson, C.-R. Lu et al., “Presynaptic low- and high-affinity kainate receptors in nociceptive spinal afferents,” *Pain*, vol. 120, no. 1-2, pp. 97–105, 2006.

S. M. Carlton and G. L. Hargett, “Colocalization of metabotropic glutamate receptors in rat dorsal root ganglion cells,” *Journal of Comparative Neurology*, vol. 501, no. 5, pp. 780–789, 2007.

C. Goudet, V. Magnaghi, M. Landry, F. Nagy, R. W. Gereau IV, and J.-P. Pin, “Metabotropic receptors for glutamate and GABA in pain,” *Brain Research Reviews*, vol. 60, no. 1, pp. 43–56, 2009.

J. L. Rozas, “Metabotropic actions of kainate receptors in dorsal root ganglion cells,” *Advances in Experimental Medicine and Biology*, vol. 717, pp. 69–80, 2011.

H. Tsujino, E. Kondo, T. Fukuoka et al., “Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury,” *Molecular and Cellular Neurosciences*, vol. 15, no. 2, pp. 170–182, 2000.

H. Hyatt Sachs, R. C. Schreiber, S. E. Shoemaker, A. Sabe, E. Reed, and R. E. Zigmond, “Activating transcription factor 3 induction in sympathetic neurons after axotomy: Response to decreased neurotrophin availability,” *Neuroscience*, vol. 150, no. 4, pp. 887–897, 2007.

R. Seijffers, C. D. Mills, and C. J. Woolf, “ATF3 increases the intrinsic growth state of DRG neurons to enhance peripheral nerve regeneration,” *The Journal of Neuroscience*, vol. 27, no. 30, pp. 7991–7920, 2007.

S. Honma, M. Kawano, S. Hayashi, H. Kawano, and S. Hisano, “Expression and immunohistochemical localization of vesicular glutamate transporter 2 in the migratory pathway from the rat olfactory placode,” *European Journal of Neuroscience*, vol. 20, no. 4, pp. 923–936, 2004.

N. Bérubé-Carrière, M. Riad, G. Dal Bo, D. Lévesque, L.-É. Trudeau, and L. Descarries, “The dual dopamine-glutamate phenotype of growing mesencephalic neurons regresses in mature rat brain,” *Journal of Comparative Neurology*, vol. 517, no. 6, pp. 873–891, 2009.

G. M. Fortin, M. J. Bourque, J. A. Mendez et al., “Glutamate corelease promotes growth and survival of midbrain dopamine neurons,” *The Journal of Neuroscience*, vol. 32, pp. 17477–17491, 2012.

M. P.Mattson, “Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders,” *NeuroMolecular Medicine*, vol. 3, no. 2, pp. 65–94, 2003.

R. Balazs, “Trophic effect of glutamate,” *Current Topics in Medicinal Chemistry*, vol. 6, no. 10, pp. 961–968, 2006.

S.-H. Woo, Y. Baba, A. M. Franco, E. A. Lumpkin, and D. M. Owens, “Excitatory glutamate is essential for development and maintenance of the piloneural mechanoreceptor,” *Development*, vol. 139, no. 4, pp. 740–748, 2012.

J. Williams, “How does a vesicle know it is full?” *Neuron*, vol. 18, no. 5, pp. 683–686, 1997.

R. W. Daniels, C. A. Collins, M. V. Gelfand et al., “Increased expression of the Drosophila vesicular glutamate transporter leads to excess glutamate release and a compensatory decrease..."
in quantal content,” *The Journal of Neuroscience*, vol. 24, no. 46, pp. 10466–10474, 2004.

[287] S. Roseth, E. M. Fykse, and F. Fonnum, “Uptake of L-glutamate into rat brain synaptic vesicles: effect of inhibitors that bind specifically to the glutamate transporter,” *Journal of Neuroscience*, vol. 65, no. 1, pp. 96–103, 1995.

[288] Z. He, L. Yan, Z. Yong, Z. Dong, H. Dong, and Z. Gong, “Chicago sky blue 6B, a vesicular glutamate transporters inhibitor, attenuates methamphetamine-induced hyperactivity and behavioral sensitization in mice, Behav,” *Behavioural Brain Research*, vol. 239, pp. 172–176, 2013.

[289] A. Beirith, A. R. S. Santos, and J. B. Calixto, “Mechanisms underlying the nociception and paw oedema caused by injection of glutamate into the mouse paw,” *Brain Research*, vol. 924, no. 2, pp. 219–228, 2002.

[290] N. Pietrancosta, A. Kessler, F.-C. Favre-Besse et al., “Rose Bengal analogs and vesicular glutamate transporters (VGLUTs),” *Bioorganic and Medicinal Chemistry*, vol. 18, no. 18, pp. 6922–6933, 2010.

[291] H. Omote, T. Miyaji, N. Juge, and Y. Moriyama, “Vesicular neurotransmitter transporter: bioenergetics and regulation of glutamate transport,” *Biochemistry*, vol. 50, no. 25, pp. 5558–5565, 2011.

[292] D. N. Ruskin and S. A. Masino, “The nervous system and metabolic dysregulation: emerging evidence converges on ketogenic diet therapy,” *Frontiers in Neuroscience*, vol. 6, p. 33, 2012.

[293] D. N. Ruskin, M. Kawamura Jr., and S. A. Masino, “Reduced pain and inflammation in juvenile and adult rats fed a ketogenic diet,” *PLoS ONE*, vol. 4, no. 12, Article ID e8349, 2009.

[294] T. M. Lund, Ø. Riså, U. Sonnewald, A. Schousboe, and H. S. Waagepetersen, “Availability of neurotransmitter glutamate is diminished when β-hydroxybutyrate replaces glucose in cultured neurons,” *Journal of Neurochemistry*, vol. 110, no. 1, pp. 80–91, 2009.

[295] N. Juge, J. A. Gray, H. Omote et al., “Metabolic control of vesicular glutamate transport and release,” *Neuron*, vol. 68, no. 1, pp. 99–112, 2010.

[296] S. O. Heyliger, C. B. Goodman, J. M. Ngong, and K. F. A. Soliman, “The analgesic effects of tryptophan and its metabolites in the rat,” *Pharmacological Research*, vol. 38, no. 4, pp. 243–250, 1998.

[297] F. Fazio, L. Lionetto, G. Molinaro et al., “Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors,” *Molecular Pharmacology*, vol. 81, no. 5, pp. 643–656, 2012.

[298] S. A. Neale, C. S. Copeland, V. N. Uebele, F. J. Thomson, and T. E. Salt, “Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors,” *Neuropsychopharmacology*, vol. 38, pp. 1060–1067, 2013.

[299] C. N. Carrigan, R. D. Bartlett, C. S. Esslinger et al., “Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport,” *Journal of Medicinal Chemistry*, vol. 45, no. 11, pp. 2260–2276, 2002.

[300] S. A. Patel, J. O. Nagy, E. D. Bolstad, J. M. Gerdes, and C. M. Thompson, “Tetrapeptide inhibitors of the glutamate vesicular transporter (VGLUT),” *Bioorganic and Medicinal Chemistry Letters*, vol. 17, no. 18, pp. 5125–5128, 2007.

[301] G. Sanacora, C. A. Zarate, J. H. Krystal, and H. K. Manji, “Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders,” *Nature Reviews Drug Discovery*, vol. 7, no. 5, pp. 426–437, 2008.

[302] T. J. Coderre, N. Kumar, C. D. Lefebvre, and J. S. C. Yu, “A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain,” *Journal of Neuroscience*, vol. 100, no. 5, pp. 1289–1299, 2007.

[303] M. E. Fundytus, “Glutamate receptors and nociception: implications for the drug treatment of pain,” *CNS Drugs*, vol. 15, no. 1, pp. 29–58, 2001.

[304] G.-A. Gaudreau and V. Plourde, “Involvement of N-methyl-D-aspartate (NMDA) receptors in a rat model of visceral hypersensitivity,” *Behavioural Brain Research*, vol. 150, no. 1-2, pp. 185–189, 2004.

[305] J. Sawynok, “Topical and peripherally acting analgesics,” *Pharmacological Reviews*, vol. 55, no. 1, pp. 1–20, 2003.

[306] S. M. Carlton, “Peripheral NMDA receptors revisited: hope floats,” *Pain*, vol. 146, no. 1-2, pp. 1–2, 2009.

[307] E. M. Hoffman and K. E. Miller, “Peripheral inhibition of glutaminase reduces carrageenan-induced Fos expression in the superficial dorsal horn of the rat,” *Neuroscience Letters*, vol. 472, no. 3, pp. 157–160, 2010.